mhtx_10q.htm

0001477932-21-003259.txt : 20210517 0001477932-21-003259.hdr.sgml : 20210517 20210517125631 ACCESSION NUMBER: 0001477932-21-003259 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210517 DATE AS OF CHANGE: 20210517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MANHATTAN SCIENTIFICS INC CENTRAL INDEX KEY: 0001099132 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 850460639 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-28411 FILM NUMBER: 21929051 BUSINESS ADDRESS: STREET 1: 244 FIFTH AVENUE STREET 2: SUITE 2341 CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-541-2405 MAIL ADDRESS: STREET 1: 244 FIFTH AVENUE STREET 2: SUITE 2341 CITY: NEW YORK STATE: NY ZIP: 10001 10-Q 1 mhtx_10q.htm FORM 10-Q mhtx_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ____________ to ____________

MANHATTAN SCIENTIFICS, INC.

(Exact name of small business issuer as specified in its charter)

Delaware

000-28411

85-0460639

(State of

Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

244 Fifth Ave, Suite 2341

New York, New York, 10001

(Address of principal executive offices) (Zip code)

Issuer’s telephone number: (212) 541-2405

Securities registered under Section 12(b) of the Exchange Act: None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, $0.001 par value

(Title of Class)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company . See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

There were 559,281,064 shares outstanding of registrant’s common stock, par value $0.001 per share, as of May 12, 2021.

TABLE OF CONTENTS

PART I

Item 1.	Condensed Consolidated Financial Statements	3
	Condensed Consolidated Balance Sheets as of March 31, 2021 (unaudited) and December 31, 2020		3
	Condensed Consolidated Statements of Operations for the three months ended March 31, 2021 and 2020 (unaudited)		4
	Condensed Consolidation Statements of Stockholders’ Equity (Deficit) for the three months ended March 31, 2021 and 2020 (unaudited)		5
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020 (unaudited)		6
	Notes to Condensed Consolidated Financial Statements (Unaudited)		7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operation		15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		20
Item 4.	Controls and Procedures		21

PART II

Item 1.	Legal Proceedings		22
Item 1A.	Risk Factors		22
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		22
Item 3.	Defaults Upon Senior Securities		22
Item 4.	Mine Safety Disclosure		22
Item 5.	Other Information		22
Item 6.	Exhibits		22
SIGNATURES			23

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS


	March 31,			December 31,
	2021			2020
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	254,000		$	353,000
Prepaid expenses		17,000			12,000
Due from the sale of assets - current portion		300,000			300,000
Total current assets		571,000			665,000

Investment in equity securities		6,199,000			5,875,000
Property and equipment, net		8,000			6,000
Due from the sale of assets		300,000			300,000
Other assets		2,000			2,000
Total assets	$	7,080,000		$	6,848,000

LIABILITIES
Current liabilities:
Accounts payable and accrued expenses	$	169,000		$	159,000
Accrued expenses - related parties		935,000			853,000
Total current liabilities		1,104,000			1,012,000

Long-term liabilities:
Notes payable, net of discounts		110,000			104,000
Total long-term liabilities		110,000			104,000
Total liabilities		1,214,000			1,116,000

Commitments and Contingencies - Note 7

Series D convertible preferred mandatory redeemable, authorized 105,761 shares, 105,761 and 105,761 shares issued and outstanding, respectively		1,058,000			1,058,000

STOCKHOLDERS’ EQUITY
Capital stock $.001 par value
Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively		-			-
Class A Convertible Preferred, authorized 182,525, 0 and 0 shares issued and outstanding, respectively		-			-
Class B Convertible Preferred, authorized 250,000, 49,999 and 49,999 shares issued and outstanding, respectively		-			-
Class C Redeemable Convertible Preferred, authorized 14,000, 0 and 0 shares issued and outstanding, respectively		-			-
Common, authorized 950,000,000 shares, 559,281,064 and 559,281,064 shares issued, and outstanding, respectively		559,000			559,000
Additional paid-in-capital		68,996,000			68,996,000
Accumulated deficit		(64,747,000	)		(64,881,000	)
Total stockholders' equity		4,808,000			4,674,000
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY	$	7,080,000		$	6,848,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

	THREE MONTHS ENDED
	MARCH 31,
	2021			2020

Revenue	$	-		$	-

Operating costs:
General and administrative expenses		181,000			169,000
Research and development		3,000			3,000

Total operating costs and expenses		184,000			172,000

Loss from operations before other income and expenses		(184,000	)		(172,000	)

Other income and (expenses):
Gain (Loss) on fair value adjustment of investments		324,000			(553,000	)
Interest expense		(6,000	)		(7,000	)
Total other income (expense)		318,000			(560,000	)

NET INCOME (LOSS)	$	134,000		$	(732,000	)

INCOME (LOSS) PER COMMON SHARE:

Weighted average number of common shares outstanding (Basic)		559,281,064			557,781,064

Basic income (loss) per common share	$	0.00		$	(0.00	)

Weighted average number of common shares outstanding (Diluted)		570,737,981			557,781,064

Diluted income (loss) per common share	$	0.00		$	(0.00	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

FOR THE THREE MONTHS ENDED MARCH 31, 2021 and 2020

(unaudited)

Preferred Stock - Series B

Common Stock

Additional

Total

$0.001 Par Value

Paid-In

Accumulated

Shareholders'

Shares

Amount

Shares

Amount

Capital

Deficit

Equity

Balance

December 31, 2020

49,999

559,281,064

559,000

68,996,000

(64,881,000

)

4,674,000

Net income

134,000

Balance

March 31, 2021

49,999

559,281,064

559,000

68,996,000

(64,747,000

)

4,808,000


	Preferred Stock - Series B				Common Stock				Additional					Total
	$0.001 Par Value				$0.001 Par Value				Paid-In		Accumulated			Shareholders'
	Shares		Amount		Shares		Amount		Capital		Deficit			Deficit

Balance
December 31, 2019		49,999	$	-		557,781,064	$	558,000	$	67,632,000	$	(69,195,000	)	$	(1,005,000	)

Net loss		-		-		-		-		-		(732,000	)		(732,000	)

Balance
March 31, 2020		49,999	$	-		557,781,064	$	558,000	$	67,632,000	$	(69,927,000	)	$	(1,737,000	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)

	THREE MONTHS ENDED
	MARCH 31,
	2021			2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	134,000		$	(732,000	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization		1,000			-
Loss (Gain) on fair value adjustment of investments		(324,000	)		553,000
Amortization of debt discount		6,000			7,000
Changes in:
Prepaid expenses		(5,000	)		(5,000	)
Accounts payable and accrued expenses		10,000			77,000
Accounts payable and accrued expenses - related party		82,000			-

Net cash used in operating activities		(96,000	)		(100,000	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets		(3,000	)		(4,000	)
Proceeds from sale of investments		-			84,000

Net cash provided by (used in) investing activities		(3,000	)		80,000

CASH FLOWS FROM FINANCING ACTIVITIES:
Net cash provided by financing activities		-			-

NET DECREASE IN CASH		(99,000	)		(20,000	)
CASH, BEGINNING OF PERIOD		353,000			261,000

CASH, END OF PERIOD	$	254,000		$	241,000

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	$	-		$	-
Income taxes paid	$	-		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(UNAUDITED)

NOTE 1 – BASIS OF PRESENTATION

The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2020, filed on April 15, 2021. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented.

Operating results for the three months period ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.

As of March 31, 2021, the Company has an accumulated deficit of $64,747,000 and negative working capital of $533,000. Because of these conditions, the Company will require additional working capital to develop business operations. The Company intends to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations.

As of the filing date, the Coronavirus (“COVID-19”) has caused significant volatility in global markets, including the market price of our securities. The demand for our products and services has decreased and the ability of our customers to make payments for the products and services they purchased has been negatively impacted.

These factors raise substantial doubt about the Company’s ability to continue within one year from the date of filing. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

The ability to continue as a going concern is dependent on out generating cash from the sale of our common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plan includes selling our equity securities and/or obtaining debt financing to fund our capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION:

The condensed consolidated financial statements include the accounts of Manhattan Scientific, Inc., and its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated.

USE OF ESTIMATES:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(UNAUDITED)

CASH AND CASH EQUIVALENTS:

The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows.

CASH CONCENTRATION:

The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of March 31, 2021 and December 31, 2020, we had cash balances of $0 and $143,000 exceeding the federally insured limits.

PROPERTY AND EQUIPMENT:

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets, the useful lives range between 3-10 years, using the straight-line method for financial statement purposes.

INTANGIBLE ASSETS:

License Agreements

In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2021 and December 31, 2020, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2021 and December 31, 2020, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.

DUE FROM THE SALE OF ASSETS:

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.

During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement, May 1. During May 2020, the Company received $300,000 and reduced the due from the sale of assets. During April 2021, the Company received $300,000 and reduced the due from the sale of assets. As of March 31, 2021, the Company evaluated the collectability and determined that no allowance is needed at this time due to the payment history with this third party and the subsequent receipt of funds.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(UNAUDITED)

MARKETABLE SECURITIES:

The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within other income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other income (loss). For the three months ended March 31, 2021, no allowance was recorded for credit losses.

REVENUE RECOGNITION:

The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.

Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.

FAIR VALUE OF FINANCIAL INSTRUMENTS:

The Company recognized the fair value of financial instruments in accordance with FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis. Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of March 31, 2021 and December 31, 2020 because of the relative short term nature of these instruments.

During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(UNAUDITED)

As of March 31, 2021, the Company holds 52,516,508 shares of Imagion and is reported under fair value method under ASC 320. Any change in the value is reported on the income statement as an unrealized gain or loss.

Our financial assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2020 and December 31, 2020, consisted of the following:

	Total fair value at March 31, 2021		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	6,199,000	$	6,199,000	$	-	$	-

	Total fair value at December 31, 2020		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	5,875,000	$	5,875,000	$	-	$	-

LEASES

The Company leases a facility with terms of month to month for its headquarters. The Company adopted ASC 842 on January 1, 2019 and has evaluated that has no impact on the financial statements as under the practical expedient the leases consist of terms less than one year, and therefore is not required to capitalize the lease.

During June 2019, the Company entered into an assignment and assumption of lease with the landlord and another entity for the lease term through April 2021.

INCOME TAXES

The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations.

ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return.

Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(UNAUDITED)

BASIC AND DILUTED EARNINGS (LOSS) PER SHARE

In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net income (loss) per share excludes the dilutive effect of stock options or warrants and convertible notes Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of March 31, 2021 and 2020, 0 and 31,697,917, respectively, dilutive shares were excluded from the calculation of diluted earnings (loss) per common share, as the effect of these shares on earnings per share would have been anti-dilutive; however, dilutive shares were included from the calculation of diluted income common shares for the three months ended March 31, 2021.

The following table shows the computation of basic and diluted earnings (loss) per share for the three months ended March 31, 2021 and 2020:

	Three Months Ended
	March 31, 2021		March 31, 2020
Numerator:
Net income (loss)	$	134,000	$	(732,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064		557,781,064
Effect of dilutive securities		11,456,917		-
Weighted-average diluted shares		570,737,981		549,364,626

Basic earnings (loss) per share	$	0.00	$	(0.00	)
Diluted earnings (loss) per share	$	0.00	$	(0.00	)

STOCK BASED COMPENSATION

In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019. Upon adoption, there was no material impact to the financial statements.

RECENT ACCOUNTING PRONOUNCEMENTS

In August 2018, the FASB issued ASU 2018-13, Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement, which removes, modifies, and adds certain disclosure requirements related to fair value measurements in ASC Topic 820. This guidance is effective for public companies in fiscal years beginning after December 15, 2019, with early adoption permitted. Effective January 1, 2020, we adopted ASU 2018-13. The implementation of this standard did not have any material impact on our consolidated financial statements.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(UNAUDITED)

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years.

The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Company’s results of operations, financial position or cash flow.

The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.

NOTE 3 – INVESTMENT IN IMAGION BIOSYSTEMS

As of March 31, 2021, the Company owns 52,516,508 shares of Imagion, resulting in a noncontrolling interest of Imagion’s issued and outstanding common stock. Based upon Imagion’s trading price on March 31, 2021, approximately $0.12 per share, the fair value of the Imagion shares was approximately $6,199,000. During the three months ended March 31, 2021, the Company recorded an unrealized gain in its investment of $324,000.

Below is reconciliation for the changes to the investment in Imagion for the three months ended March 31, 2020:

Balance as of December 31, 2020	$	5,875,000
Change in the unrealized fair value of securities		324,000
Balance as of March 31, 2021	$	6,199,000

NOTE 4 – NOTES PAYABLE

On October 17, 2019, The Company executed a secured note with a related party for $100,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.015 per share with 2 million shares of IBX common stock. The amortization of debt discount for the three months ended March 31, 2021 was $4,000.

On October 17, 2019, The Company executed a secured note with an individual for $50,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.015 per share with 1 million shares of IBX common stock. The amortization of debt discount for the three months ended March 31, 2021 was $2,000.

Notes payable	$	150,000
Less: Discounts on notes payable		(40,000	)
Notes payable, net of discounts	$	110,000

NOTE 5 – CAPTIAL TRANSACTIONS

Stock Activity

During the three months ended March 31, 2021, the Company had not issued common stock.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(UNAUDITED)

Options

On March 22, 2021, the Company entered into a settlement with a third party, which the Company granted 15,000,000 shares of common stock options to purchase 15,000,000 shares of common stock at an exercise price of $0.0154. The options price was based on the closing market price of common stock on October 1, 2020. The Settlement is for the Employment Agreement with a third party, dated January 12, 2015 to which the Company agreed to issued common shares.

At March 31, 2021, the 32,500,000 outstanding options had an aggregate intrinsic value of $1,595,000. A summary of the Company’s stock option activity and related information is as follows:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Life		Number of Options Exercisable		Aggregate Intrinsic Value
Outstanding as of December 31, 2020		18,500,000		$	0.07		2.84		18,500,000	$	1,295,000
Granted		15,000,000			0.02		9.30		15,000,000		300,000
Exercised		-			-		-		-
Expired		(1,000,000	)		0.06		-		-
Outstanding as of March 31, 2021		32,500,000		$	0.07		5.87		32,500,000	$	1,595,000

Exercise prices and weighted-average contractual lives of 32,500,000 stock options outstanding as of March 31, 2021 are as follows:

				Options Outstanding				Options Exercisable
Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	0.05		3,000,000		4.25	$	0.05		3,000,000	$	0.05
$	0.06		5,000,000		4.35	$	0.06		5,000,000	$	0.06
$	0.07		6,000,000		0.35	$	0.07		6,000,000	$	0.07
$	0.14		3,000,000		3.25	$	0.14		3,000,000	$	0.14
$	0.02		15,500,000		9.30	$	0.02		15,500,000	$	0.02

The fair value for options granted were determined using the Black-Scholes option-pricing model.

The Company did not recognize compensation expense During the three months ended March 31, 2021.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(UNAUDITED)

NOTE 6 – LICENSE AGREEMENT

On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products.

During the three months ended March 31, 2021, the Company received $0 as a minimum royalty payment.

NOTE 7 – COMMITMENTS AND CONTINGENCIES

Legal matter contingencies

The Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company. Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted. Once established, such provisions are adjusted when there is more information available of when an event occurs requiring a change.

NOTE 8 – RELATED PARTY TRANSACTIONS

As of March 31, 2021 and December 31, 2020, the Company had accrued expenses to related parties of approximately $935,000 and $853,000.

As of March 31, 2021, the amounts are due to the Company’s sole officer for compensation $247,000 and the chairman of the board for compensation of $633,000 and the members of the board of directors of $55,000.

NOTE 9 – SUBSEQUENT EVENTS

In accordance with ASC 855-10, the Company has analyzed its operations subsequent to March 31, 2021 to the date these financial statements were issued, and there were no other material subsequent events to disclose in these financial statements, except as noted.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Forward Looking Statements

This Form 10-Q contains “forward-looking” statements including statements regarding our expectations of our future operations. For this purpose, any statements contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” or “continue” or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. These factors include, but are not limited to, economic conditions generally and in the industries in which we may participate. In addition, these forward-looking statements are subject, among other things, to our successful completion of the research and development of our technologies; successful commercialization of our technologies; successful protection of our patents; and effective significant industry competition from various entities whose research and development, financial, sales and marketing and other capabilities far exceeds ours. In light of these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, we undertake no obligation to announce publicly revisions we make to these forward-looking statements to reflect the effect of events or circumstances that may arise after the date of this report.

OVERVIEW

Manhattan Scientifics, Inc. (the “Company” or “Manhattan Scientifics”), a Delaware corporation, was established on July 31, 1992 and has one operating wholly-owned subsidiary: Metallicum, Inc., (“Metallicum”). Manhattan Scientifics is focused on technology transfer and commercialization of these transformative technologies.

The Company operates as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in various fields, with emphasis in the areas of nanotechnology. Nanotechnology is the use and manipulation of matter on an atomic and molecular scale. To achieve this goal, the Company is actively seeking to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, scientists and leaders in industry and government. The Company and its executives have a long-standing relationship with Los Alamos Laboratories in New Mexico.

Metallicum

In June 2008, we acquired Metallicum and its licensed patented technology. We entered into a stock purchase agreement with Metallicum to acquire all of the outstanding capital in exchange for 15,000,000 restricted shares of our common stock. An additional 15,000,000 shares of our common stock will be payable to Metallicum in the event of meeting certain milestones. At December 31, 2011, one milestone was met. Metallicum was granted an exclusive license by The Los Alamos National Laboratory on patents related to nanostructured metals. In September 2009, we entered into a technology transfer agreement and sale with Carpenter Technology Corporation, (“Carpenter”) wherein Carpenter was to fully develop, manufacture and market a new class of high strength metals. On February 11, 2015, the Company and Carpenter entered into a Settlement Agreement and Mutual Release pursuant to which the parties provided a full release of one another, Carpenter paid the Company $8,000,000, Carpenter transferred to the Company all intellectual and physical property that was part of the original agreement, Carpenter agreed to provide follow-on technical assistance and Carpenter provided a list of all customers and contacts.

On May 1, 2019, Manhattan Scientifics, Inc., a Delaware corporation (the “Company”), and Metallicum, Inc., a wholly-owned subsidiary of the Company, entered into an Overarching Agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. The Company anticipates royalty income as the nanotitanium is commercialized for use in medial prosthetics. Royalties will be 10% on sales of licensed dental products and an average of 5% in all other sales of licensed products.

Table of Contents

Imagion

On May 31, 2011, we entered into an Agreement and Plan of Reorganization to acquire Senior Scientific. The total purchase price was 21,668,000 restricted shares of our common stock (less 7,667,000 shares previously issued pursuant to an option agreement). As a result of this acquisition, Senior Scientific owned patented technologies that can use biosafe nanoparticles and sensitive magnetic sensors to detect and measure cancer cells in biopsies or in the human body with the potential to transform how cancer is detected and treated. On November 17, 2016, Senior Scientific merged with and into Imagion, a Nevada company. Following the merger, Imagion held all of the liabilities, obligations and assets of Senior Scientific and the Company continued as the sole equity holder of Imagion. On November 29, 2016, the Company announced a plan to have Imagion pursue an IPO and listing on the Australian Stock Exchange (ASX).

As of March 31, 2021, Manhattan Scientifics presently owns 52,516,508 shares of Imagion, with a fair market value of approximately $6,199,000, based upon the closing price per share of Imagion common stock on the Australian Stock Exchange. The Company accounts for its investment in Imagion in accordance with ASC 825-10 and elected fair value option. We initially held 31% of the total issued and outstanding shares of Imagion and had one seat on the Board of Directors of Imagion. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.

Novint

We made an investment in Novint Technologies Inc. (“Novint”) in 2001. Novint is currently engaged in the development and sale of 3D haptics products and equipment. Haptics refers to one’s sense of touch and Novint’s focus is in the consumer interactive computer gaming market. The Company owns 1,028,425 shares of Novint’s common stock. The fair value of the Novint shares are not recorded on the balance sheet as of March 31, 2021.

RESULTS OF OPERATIONS

THREE MONTHS ENDED MARCH 31, 2021 COMPARED TO THREE MONTHS ENDED MARCH 31, 2020

GENERAL AND ADMINISTRATIVE. General and administrative expenses consist of consultants, contractors, accounting, legal, travel, rent, telephone and other day-to-day operating expenses. General and administrative expenses were $181,000 for the three months ended March 31, 2021 compared with $169,000 for the three months ended March 31, 2020. The primary increase in general and administrative expenses was the result of the increase in accounting fees and legal fees.

RESEARCH AND DEVELOPMENT. Research and development costs were $3,000 for the three months ended March 31, 2021 compared with $3,000 for the three months ended March 31, 2020.

OTHER INCOME (EXPENSES). Total other income for the three months ended March 31, 2021 totaled $318,000 compared to the total other expenses of $560,000 for the three months ended March 31, 2020. This is primarily attributable to the increase in the gain on fair value adjustments of its investment in Imagion during the period.

NET INCOME (LOSS). During the three months ended March 31, 2021, the Company had net income of $134,000, compared to a net loss of $732,000 for the three months ended March 31, 2020. This is primarily attributable to the gain on fair value adjustment of investment, partially offset by an increase in general and administrative expenses.

LIQUIDITY AND CAPITAL RESOURCES

The Company had Stockholders’ equity of $4,808,000 and the working capital deficit was $533,000 on March 31, 2021. The Company had a decrease of $99,000 in cash and cash equivalents for the three months ended March 31, 2021.

Table of Contents

Based upon current projections, our principal cash requirements for the next 12 months consists of (1) fixed expenses, including consulting and professional services and (2) variable expenses, including technology research and development, milestone payments and intellectual property protection, and additional scientific consultants. As of March 31, 2021, we had $254,000 in cash. We believe our current cash position may not be sufficient to maintain our operations for the next twelve months. Accordingly, we may need to engage in equity or debt financings to secure additional funds. If we raise additional funds through future issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock. Any debt financing that we secure in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to support our business growth and to respond to business challenges could be impaired, and our business may be harmed.

On October 17, 2019, we executed a secured note with our only independent director for $100,000 and a secured note with an unrelated party for $50,000. The secured notes are due on October 17, 2022. The Company agreed that the notes bear interest at 10% per annum, to be paid in advance with shares of Imagion Biosystems Limited common stock (“IBX”), calculated at $0.015 per share or 3,000,000 shares of IBX. We currently do not plan any further sale of transfer of IBX common stock to raise funds for operations. To fund operations, we plan on relying on payments of $600,000, to be collected during the next two years in equal increments from the sale of assets in 2019 and future royalties from the Metallicum license.

CASH FLOW INFORMATION

The Company had cash and cash equivalents of approximately $254,000 and $353,000 at March 31, 2021 and December 31, 2020, respectively. This represents a decrease in cash of $99,000.

OPERATING ACTIVITIES

The Company used approximately $96,000 of cash for operating activities in the three months ended March 31, 2021 as compared to using $100,000 of cash for operating activities in the three months ended March 31, 2020. The reason for the decrease in cash used for operating activities is an increase in current liabilities partially offset by a net income after adjustment for non-cash items

INVESTING ACTIVITIES

The Company used approximately $3,000 of cash for investing activities in the three months ended March 31, 2021 as compared to receiving $80,000 of cash for investing activities in the three months ended March 31, 2020. This decrease in cash received in investing activities, is primarily attributed to proceeds from sale of investment of Imagion Biosystems shares during the three months ended March 31, 2020.

FINANCING ACTIVITIES

During the three months ended March 31, 2021 and 2020, the Company had no financing activities.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of our patents, fair value of our common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

Table of Contents

Fair Value of Financial Instruments:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

As of March 31, 2021, the Company holds 52,516,508 shares of Imagion and is reported under fair value method under ASC 320. Management determined that it was appropriate to carry its investment in Imagion at fair value because the investment is traded on the Australian stock exchange and has daily trading activity and is a better indicator of value. The investments are re-measured at the end of each quarter based on the trading price and converted from AUD to USD. Any change in the value is reported on the income statement as an unrealized gain or loss.

Property and equipment:

License Agreements:

In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2021, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. As the three months ended March 31, 2021, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.

Table of Contents

Due from the Sale of Assets:

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Marketable Securities:

Revenue Recognition:

Accounting for Leases:

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance: ASU 2017-13, ASU 2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01 (collectively, Topic 842). Topic 842 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company early adopted Topic ASC 842 using the effective date of January 1, 2019 as the date of our initial application of the standard. The Company used the new transition election to not restate comparative periods and elected the package of practical expedients upon adoption, which permits the Company to not reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. Consequently, financial information for the comparative periods will not be updated. Upon adoption, there was no material impact to the financial statements.

Table of Contents

Stock Based Compensation:

Basic and Diluted Earnings (Loss) Per Share:

OFF BALANCE SHEET ARRANGEMENTS

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations liquidity, capital expenditures or capital resources and would be considered material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to include disclosure under this item.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

We conducted an evaluation under the supervision and with the participation of our management, of the effectiveness of the design and operation of our disclosure controls and procedures. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive and principal financial officers concluded as of March 31, 2021 that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses in our internal controls over financial reporting discussed immediately below.

Identified Material Weakness

A material weakness in our internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected.

Management identified the following material weakness during its assessment of internal controls over financial reporting:

Resources: We had one full-time employee in general management and no full-time employees with the requisite expertise in the key functional areas of finance and accounting. As a result, there is a lack of proper segregation of duties necessary to insure that all transactions are accounted for accurately and in a timely manner.

Written Policies & Procedures: We need to prepare written policies and procedures for accounting and financial reporting to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity transactions, and prepare, review and submit SEC filings in a timely manner.

Audit Committee: We do not have, and are not required, to have an audit committee. An audit committee would improve oversight in the establishment and monitoring of required internal controls and procedures.

(b) Change in Internal Control Over Financial Reporting

No changes.

Table of Contents

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are subject from time to time to litigation, claims and suits arising in the ordinary course of business. As of March 31, 2021, we were not a party to any material litigation, claim or suite whose outcome could have a material effect on our financial statements.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

Index to Exhibits

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

EX-101.INS**		XBRL Instance Document

EX-101.SCH**		XBRL Taxonomy Extension Schema Document

EX-101.CAL**		XBRL Taxonomy Extension Calculation Linkbase

EX-101.DEF**		XBRL Taxonomy Extension Definition Linkbase

EX-101.LAB**		XBRL Taxonomy Extension Labels Linkbase

EX-101.PRE**		XBRL Taxonomy Extension Presentation Linkbase

_________________

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 17^th day of May, 2021.

	MANHATTAN SCIENTIFICS, INC.

	By:	/s/ Emmanuel Tsoupanarias
	Name:	Emmanuel Tsoupanarias
	Title:	Chief Executive Officer (Principal Executive, Financial and Accounting Officer)

EX-31.1 2 mhtx_ex311.htm CERTIFICATION mhtx_ex311.htm

EXHIBIT 31.1

CERTIFICATIONS

I, Emmanuel Tsoupanarias, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2021 (the “report”) of Manhattan Scientifics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 17, 2021	By:	/s/ Emmanuel Tsoupanarias
		Emmanuel Tsoupanarias
		Chief Executive Officer
		(principal executive, financial and accounting officer)

EX-32.1 3 mhtx_ex321.htm CERTIFICATION mhtx_ex321.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Manhattan Scientifics, Inc., a Delaware corporation (the “Company”), does hereby certify, to the best of his knowledge, that:

	(1)	The Quarterly Report of Form 10-Q for the period ending March 31, 2021 (the “Report”) of the Company complies in all material respects with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 17, 2021	By:	/s/ Emmanuel Tsoupanarias
		Emmanuel Tsoupanarias
		Chief Executive Officer
		(principal executive, financial and accounting officer)

EX-101.INS 4 mhtx-20210331.xml XBRL INSTANCE DOCUMENT 0001099132 2021-01-01 2021-03-31 0001099132 mhtx:BoardOfDirectorMember 2021-03-31 0001099132 mhtx:ChairmanMember 2021-03-31 0001099132 mhtx:SoleOfficerMember 2021-03-31 0001099132 mhtx:OctoberOneTwoThousandTwentyMember 2021-01-01 2021-03-31 0001099132 2021-03-01 2021-03-22 0001099132 mhtx:ExercisePriceRangeSixMember 2020-12-31 0001099132 mhtx:ExercisePriceRangeSevenMember 2020-01-01 2020-12-31 0001099132 mhtx:ExercisePriceRangeSixMember 2020-01-01 2020-12-31 0001099132 mhtx:ExercisePriceRangeFourMember 2020-01-01 2020-12-31 0001099132 mhtx:ExercisePriceRangeThreeMember 2020-01-01 2020-12-31 0001099132 mhtx:ExercisePriceRangeTwoMember 2020-01-01 2020-12-31 0001099132 mhtx:ExercisePriceRangeSevenMember 2020-12-31 0001099132 mhtx:ExercisePriceRangeFourMember 2020-12-31 0001099132 mhtx:ExercisePriceRangeThreeMember 2020-12-31 0001099132 mhtx:ExercisePriceRangeTwoMember 2020-12-31 0001099132 mhtx:RelatedPartyMember 2021-01-01 2021-03-31 0001099132 mhtx:RelatedPartyMember 2019-10-01 2019-10-17 0001099132 mhtx:IndividualsMember 2021-01-01 2021-03-31 0001099132 mhtx:IndividualsMember 2019-10-01 2019-10-17 0001099132 mhtx:ImagionBiosystemsIncMember 2021-03-31 0001099132 mhtx:PatentLicenseAgreementMember mhtx:LosAlamosNationalSecurityLLCMember mhtx:InTwoThousandNineMember 2021-01-01 2021-03-31 0001099132 2018-01-01 2018-12-31 0001099132 srt:MaximumMember 2021-01-01 2021-03-31 0001099132 srt:MinimumMember 2021-01-01 2021-03-31 0001099132 2020-01-01 2020-12-31 0001099132 2019-01-01 2019-12-31 0001099132 2020-05-01 2020-05-31 0001099132 mhtx:PatentLicenseAgreementMember mhtx:LosAlamosNationalSecurityLLCMember mhtx:InTwoThousandEightMember 2021-01-01 2021-03-31 0001099132 mhtx:SignificantUnobservableInputsMember mhtx:LevelThreeMember 2021-03-31 0001099132 mhtx:SignificantUnobservableInputsMember mhtx:LevelThreeMember 2020-12-31 0001099132 mhtx:SignificantOtherObservableInputsMember mhtx:LevelTwoMember 2021-03-31 0001099132 mhtx:SignificantOtherObservableInputsMember mhtx:LevelTwoMember 2020-12-31 0001099132 mhtx:QuotedPricesInActiveMarketsForIdenticalAssetsMember mhtx:LevelOneMember 2021-03-31 0001099132 mhtx:QuotedPricesInActiveMarketsForIdenticalAssetsMember mhtx:LevelOneMember 2020-12-31 0001099132 mhtx:TotalFairValueMember 2021-03-31 0001099132 mhtx:TotalFairValueMember 2020-12-31 0001099132 us-gaap:RetainedEarningsMember 2021-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001099132 us-gaap:CommonStockMember 2021-03-31 0001099132 mhtx:PreferredStockSeriesBMember 2021-03-31 0001099132 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001099132 us-gaap:RetainedEarningsMember 2020-12-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001099132 us-gaap:CommonStockMember 2020-12-31 0001099132 mhtx:PreferredStockSeriesBMember 2020-12-31 0001099132 2020-03-31 0001099132 us-gaap:RetainedEarningsMember 2020-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001099132 us-gaap:CommonStockMember 2020-03-31 0001099132 mhtx:PreferredStockSeriesBMember 2020-03-31 0001099132 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001099132 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001099132 mhtx:PreferredStockSeriesBMember 2020-01-01 2020-03-31 0001099132 2019-12-31 0001099132 us-gaap:RetainedEarningsMember 2019-12-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001099132 us-gaap:CommonStockMember 2019-12-31 0001099132 mhtx:PreferredStockSeriesBMember 2019-12-31 0001099132 2020-01-01 2020-03-31 0001099132 mhtx:SeriesDconvertiblepreferredStockMember 2020-12-31 0001099132 mhtx:SeriesDconvertiblepreferredStockMember 2021-03-31 0001099132 mhtx:ClassCRedeemableConvertiblePreferredStockMember 2020-12-31 0001099132 mhtx:ClassCRedeemableConvertiblePreferredStockMember 2021-03-31 0001099132 mhtx:ClassBConvertiblePreferredStockMember 2020-12-31 0001099132 mhtx:ClassBConvertiblePreferredStockMember 2021-03-31 0001099132 mhtx:ClassAConvertiblePreferredStockMember 2020-12-31 0001099132 mhtx:ClassAConvertiblePreferredStockMember 2021-03-31 0001099132 2020-12-31 0001099132 2021-03-31 0001099132 2021-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure MANHATTAN SCIENTIFICS INC 0001099132 10-Q false --12-31 true false false Yes 2021-03-31 Non-accelerated Filer FY 2021 559281064 true false Yes

254000

353000

17000

12000

300000

571000

665000

6199000

5875000

8000

6000

300000 300000

2000

7080000

6848000

169000

159000

935000

853000

1104000

1012000

110000

104000

110000

104000

1214000

1116000

1058000

0 0

559000

68996000

-64747000

-64881000

4808000

4674000

7080000

6848000

.001

447804

182525

250000

14000

105761

49999

105761

49999

105761

950000000

559281064

181000

169000

3000

184000

172000

-184000 -172000

324000

-553000

6000

7000

318000

-560000

134000

-732000

559281064

557781064

0.00

-0.00

570737981

557781064

0.00

-0.00

49999

557781064

558000

67632000

-69195000

-1005000

-732000

49999

557781064

558000

67632000

-69927000

-1737000

49999

559281064

559000

68996000

-64881000

134000

49999

559281064

559000

68996000

-64747000

1000

-324000 553000

6000

7000

-5000

10000

77000

82000 0

-96000

-100000

-3000 -4000

84000

-3000

80000

-99000

-20000

261000

241000

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2020, filed on April 15, 2021. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented.   Operating results for the three months period ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.   As of March 31, 2021, the Company has an accumulated deficit of $64,747,000 and negative working capital of $533,000. Because of these conditions, the Company will require additional working capital to develop business operations. The Company intends to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations.   As of the filing date, the Coronavirus (“COVID-19”) has caused significant volatility in global markets, including the market price of our securities. The demand for our products and services has decreased and the ability of our customers to make payments for the products and services they purchased has been negatively impacted.   These factors raise substantial doubt about the Company’s ability to continue within one year from the date of filing. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.   The ability to continue as a going concern is dependent on out generating cash from the sale of our common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plan includes selling our equity securities and/or obtaining debt financing to fund our capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">BASIS OF CONSOLIDATION:   The condensed consolidated financial statements include the accounts of Manhattan Scientific, Inc., and its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated.   USE OF ESTIMATES:   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.   CASH AND CASH EQUIVALENTS:   The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows.   CASH CONCENTRATION:   The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of March 31, 2021 and December 31, 2020, we had cash balances of $0 and $143,000 exceeding the federally insured limits.   PROPERTY AND EQUIPMENT:   Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets, the useful lives range between 3-10 years, using the straight-line method for financial statement purposes.   INTANGIBLE ASSETS:   License Agreements   In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2021 and December 31, 2020, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.   In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2021 and December 31, 2020, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.   DUE FROM THE SALE OF ASSETS:   Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.   Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.   During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement, May 1. During May 2020, the Company received $300,000 and reduced the due from the sale of assets. During April 2021, the Company received $300,000 and reduced the due from the sale of assets.  As of March 31, 2021, the Company evaluated the collectability and determined that no allowance is needed at this time due to the payment history with this third party and the subsequent receipt of funds.   MARKETABLE SECURITIES:   The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within other income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other income (loss). For the three months ended March 31, 2021, no allowance was recorded for credit losses.   REVENUE RECOGNITION:   The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.   Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.   FAIR VALUE OF FINANCIAL INSTRUMENTS:   The Company recognized the fair value of financial instruments in accordance with FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:   Level 1 — Quoted prices for identical assets and liabilities in active markets; Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.   The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis. Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of March 31, 2021 and December 31, 2020 because of the relative short term nature of these instruments.   During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.   As of March 31, 2021, the Company holds 52,516,508 shares of Imagion and is reported under fair value method under ASC 320. Any change in the value is reported on the income statement as an unrealized gain or loss.   Our financial assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2020 and December 31, 2020, consisted of the following:   <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Total fair value at March 31, 2021</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Quoted prices in active markets for identical assets (Level1)</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Significant other observable inputs (Level 2)</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Significant unobservable inputs (Level 3)</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Investment in equity securities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,199,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,199,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2">   Total fair value at December 31, 2020</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Quoted prices in active markets for identical assets (Level1)</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2">   Significant other observable inputs  (Level 2)</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2">   Significant unobservable inputs (Level 3)</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Investment in equity securities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,875,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,875,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td></tr></table>   LEASES   The Company leases a facility with terms of month to month for its headquarters. The Company adopted ASC 842 on January 1, 2019 and has evaluated that has no impact on the financial statements as under the practical expedient the leases consist of terms less than one year, and therefore is not required to capitalize the lease.   During June 2019, the Company entered into an assignment and assumption of lease with the landlord and another entity for the lease term through April 2021.   INCOME TAXES   The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations.   ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return.   Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.   BASIC AND DILUTED EARNINGS (LOSS) PER SHARE   In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net income (loss) per share excludes the dilutive effect of stock options or warrants and convertible notes Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of March 31, 2021 and 2020, 0 and 31,697,917, respectively, dilutive shares were excluded from the calculation of diluted earnings (loss) per common share, as the effect of these shares on earnings per share would have been anti-dilutive; however, dilutive shares were included from the calculation of diluted income common shares for the three months ended March 31, 2021.   The following table shows the computation of basic and diluted earnings (loss) per share for the three months ended March 31, 2021 and 2020:   <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> Three Months Ended</td> <td style="white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> March 31, 2021</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> March 31, 2020</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> Numerator:</td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" colspan="2" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" colspan="2" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Net income (loss)</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">134,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(732,000</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> Denominator:</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Weighted-average basic shares outstanding</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">557,781,064</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Effect of dilutive securities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,456,917</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Weighted-average diluted shares</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">570,737,981</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">549,364,626</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Basic earnings (loss) per share</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Diluted earnings (loss) per share</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></table>    STOCK BASED COMPENSATION   In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019. Upon adoption, there was no material impact to the financial statements.   RECENT ACCOUNTING PRONOUNCEMENTS   In August 2018, the FASB issued ASU 2018-13, Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement, which removes, modifies, and adds certain disclosure requirements related to fair value measurements in ASC Topic 820. This guidance is effective for public companies in fiscal years beginning after December 15, 2019, with early adoption permitted. Effective January 1, 2020, we adopted ASU 2018-13. The implementation of this standard did not have any material impact on our consolidated financial statements.   In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years.   The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Company’s results of operations, financial position or cash flow.   The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">As of March 31, 2021, the Company owns 52,516,508 shares of Imagion, resulting in a noncontrolling interest of Imagion’s issued and outstanding common stock. Based upon Imagion’s trading price on March 31, 2021, approximately $0.12 per share, the fair value of the Imagion shares was approximately $6,199,000. During the three months ended March 31, 2021, the Company recorded an unrealized gain in its investment of $324,000.   Below is reconciliation for the changes to the investment in Imagion for the three months ended March 31, 2020:   <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Balance as of December 31, 2020</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,875,000</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Change in the unrealized fair value of securities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">324,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Balance as of March 31, 2021</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,199,000</td> <td style="width:1%;white-space: nowrap;">  </td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">On October 17, 2019, The Company executed a secured note with a related party for $100,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.015 per share with 2 million shares of IBX common stock. The amortization of debt discount for the three months ended March 31, 2021 was $4,000.   On October 17, 2019, The Company executed a secured note with an individual for $50,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.015 per share with 1 million shares of IBX common stock. The amortization of debt discount for the three months ended March 31, 2021 was $2,000.   <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Notes payable</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,000</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Less: Discounts on notes payable</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(40,000 </td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Notes payable, net of discounts</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,000</td> <td style="width:1%;white-space: nowrap;">  </td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">Stock Activity   During the three months ended March 31, 2021, the Company had not issued common stock.  Options   On March 22, 2021, the Company entered into a settlement with a third party, which the Company granted 15,000,000 shares of common stock options to purchase 15,000,000 shares of common stock at an exercise price of $0.0154. The options price was based on the closing market price of common stock on October 1, 2020. The Settlement is for the Employment Agreement with a third party, dated January 12, 2015 to which the Company agreed to issued common shares.   At March 31, 2021, the 32,500,000 outstanding options had an aggregate intrinsic value of $1,595,000. A summary of the Company’s stock option activity and related information is as follows:   <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Number of Options</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Weighted Average Exercise Price</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Weighted Average Remaining Life</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Number of Options Exercisable</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Aggregate Intrinsic Value </td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Outstanding as of December 31, 2020</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,500,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.07</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.84</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,500,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,295,000</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Granted</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.02</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.30</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Exercised</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Expired</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,000,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.06</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;">  </td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Outstanding as of March 31, 2021</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">32,500,000</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">0.07</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">5.87</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">32,500,000</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">1,595,000</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td></tr></table>    Exercise prices and weighted-average contractual lives of 32,500,000 stock options outstanding as of March 31, 2021 are as follows:   <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="2">  </td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" colspan="2"></td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"> Options Outstanding</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"> Options Exercisable</td> <td style="white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Exercise Price</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> Number Outstanding</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> Weighted Average Remaining Contractual Life</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> Weighted Average Exercise Price </td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> Number Exercisable</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> Weighted Average Exercise Price</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td style="width:14%;">0.05</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">3,000,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">4.25</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">0.05</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">3,000,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:13%;vertical-align:bottom;text-align:right;">0.05</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td>0.06</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">5,000,000</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">4.35</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.06</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">5,000,000</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.06</td> <td style="white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td>0.07</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">6,000,000</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.35</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.07</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">6,000,000</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.07</td> <td style="white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td>0.14</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">3,000,000</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">3.25</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.14</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">3,000,000</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.14</td> <td style="white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td>0.02</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">15,500,000</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">9.30</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.02</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">15,500,000</td> <td style="white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.02</td> <td style="white-space: nowrap;">  </td></tr></table>   The fair value for options granted were determined using the Black-Scholes option-pricing model.   The Company did not recognize compensation expense During the three months ended March 31, 2021.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products.   During the three months ended March 31, 2021, the Company received $0 as a minimum royalty payment.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">Legal matter contingencies   The Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company. Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted. Once established, such provisions are adjusted when there is more information available of when an event occurs requiring a change.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">As of March 31, 2021 and December 31, 2020, the Company had accrued expenses to related parties of approximately $935,000 and $853,000.   As of March 31, 2021, the amounts are due to the Company’s sole officer for compensation $247,000 and the chairman of the board for compensation of $633,000 and the members of the board of directors of $55,000.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">In accordance with ASC 855-10, the Company has analyzed its operations subsequent to March 31, 2021 to the date these financial statements were issued, and there were no other material subsequent events to disclose in these financial statements, except as noted.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The condensed consolidated financial statements include the accounts of Manhattan Scientific, Inc., and its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of March 31, 2021 and December 31, 2020, we had cash balances of $0 and $143,000 exceeding the federally insured limits.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets, the useful lives range between 3-10 years, using the straight-line method for financial statement purposes.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">License Agreements   In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2021 and December 31, 2020, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.   In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At March 31, 2021 and December 31, 2020, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.   Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.   During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement, May 1. During May 2020, the Company received $300,000 and reduced the due from the sale of assets. During April 2021, the Company received $300,000 and reduced the due from the sale of assets.  As of March 31, 2021, the Company evaluated the collectability and determined that no allowance is needed at this time due to the payment history with this third party and the subsequent receipt of funds.</div> <div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within other income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other income (loss). For the three months ended March 31, 2021, no allowance was recorded for credit losses.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.   Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The Company recognized the fair value of financial instruments in accordance with FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:   Level 1 — Quoted prices for identical assets and liabilities in active markets; Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.   The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis. Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of March 31, 2021 and December 31, 2020 because of the relative short term nature of these instruments.   During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.   As of March 31, 2021, the Company holds 52,516,508 shares of Imagion and is reported under fair value method under ASC 320. Any change in the value is reported on the income statement as an unrealized gain or loss.   Our financial assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2020 and December 31, 2020, consisted of the following:   <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Total fair value at March 31, 2021</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Quoted prices in active markets for identical assets (Level1)</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Significant other observable inputs (Level 2)</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Significant unobservable inputs (Level 3)</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Investment in equity securities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,199,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,199,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2">   Total fair value at December 31, 2020</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Quoted prices in active markets for identical assets (Level1)</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2">   Significant other observable inputs  (Level 2)</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2">   Significant unobservable inputs (Level 3)</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Investment in equity securities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,875,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,875,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The Company leases a facility with terms of month to month for its headquarters. The Company adopted ASC 842 on January 1, 2019 and has evaluated that has no impact on the financial statements as under the practical expedient the leases consist of terms less than one year, and therefore is not required to capitalize the lease.   During June 2019, the Company entered into an assignment and assumption of lease with the landlord and another entity for the lease term through April 2021.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations.   ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return.   Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net income (loss) per share excludes the dilutive effect of stock options or warrants and convertible notes Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of March 31, 2021 and 2020, 0 and 31,697,917, respectively, dilutive shares were excluded from the calculation of diluted earnings (loss) per common share, as the effect of these shares on earnings per share would have been anti-dilutive; however, dilutive shares were included from the calculation of diluted income common shares for the three months ended March 31, 2021.   The following table shows the computation of basic and diluted earnings (loss) per share for the three months ended March 31, 2021 and 2020:   <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> Three Months Ended</td> <td style="white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> March 31, 2021</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> March 31, 2020</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> Numerator:</td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" colspan="2" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" colspan="2" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Net income (loss)</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">134,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(732,000</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> Denominator:</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Weighted-average basic shares outstanding</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">557,781,064</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Effect of dilutive securities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,456,917</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Weighted-average diluted shares</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">570,737,981</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">549,364,626</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Basic earnings (loss) per share</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Diluted earnings (loss) per share</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019. Upon adoption, there was no material impact to the financial statements.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">In August 2018, the FASB issued ASU 2018-13, Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement, which removes, modifies, and adds certain disclosure requirements related to fair value measurements in ASC Topic 820. This guidance is effective for public companies in fiscal years beginning after December 15, 2019, with early adoption permitted. Effective January 1, 2020, we adopted ASU 2018-13. The implementation of this standard did not have any material impact on our consolidated financial statements.   In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years.   The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Company’s results of operations, financial position or cash flow.   The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Total fair value at March 31, 2021</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Quoted prices in active markets for identical assets (Level1)</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Significant other observable inputs (Level 2)</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Significant unobservable inputs (Level 3)</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Investment in equity securities</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 6,199,000</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 6,199,000</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;">  </td> <td style="width:1%;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2">   Total fair value at December 31, 2020</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Quoted prices in active markets for identical assets (Level1)</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2">   Significant other observable inputs  (Level 2)</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2">   Significant unobservable inputs (Level 3)</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Investment in equity securities</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 5,875,000</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 5,875,000</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="6"> Three Months Ended</td> <td>  </td></tr> <tr style="height:15px"> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> March 31, 2021</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> March 31, 2020</td> <td>  </td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> Numerator:</td> <td style="width:1%;">  </td> <td colspan="2" style="width:9%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td colspan="2" style="width:9%;">  </td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Net income (loss)</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 134,000</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> (732,000</td> <td style="width:1%;vertical-align:bottom;"> )</td></tr> <tr style="height:15px;background-color:#ffffff"> <td>  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;">  </td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Denominator:</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;">  </td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Weighted-average basic shares outstanding</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 559,281,064</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 557,781,064</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Effect of dilutive securities</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> 11,456,917</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Weighted-average diluted shares</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 570,737,981</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 549,364,626</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td>  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;">  </td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Basic earnings (loss) per share</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 0.00</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> (0.00</td> <td style="width:1%;vertical-align:bottom;"> )</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Diluted earnings (loss) per share</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 0.00</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> (0.00</td> <td style="width:1%;vertical-align:bottom;"> )</td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Balance as of December 31, 2020</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 5,875,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Change in the unrealized fair value of securities</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> 324,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Balance as of March 31, 2021</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 6,199,000</td> <td style="width:1%;">  </td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Notes payable</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 150,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Less: Discounts on notes payable</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> (40,000 </td> <td style="width:1%;vertical-align:bottom;"> )</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Notes payable, net of discounts</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 110,000</td> <td style="width:1%;">  </td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Number of Options</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Weighted Average Exercise Price</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Weighted Average Remaining Life</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Number of Options Exercisable</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Aggregate Intrinsic Value </td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Outstanding as of December 31, 2020</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 18,500,000</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 0.07</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 2.84</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 18,500,000</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 1,295,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Granted</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 15,000,000</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 0.02</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 9.30</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 15,000,000</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 300,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Exercised</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;">  </td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Expired</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> (1,000,000</td> <td style="width:1%;vertical-align:bottom;"> )</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> 0.06</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;">  </td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Outstanding as of March 31, 2021</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 32,500,000</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 0.07</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 5.87</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 32,500,000</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 1,595,000</td> <td style="width:1%;">  </td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="2">  </td> <td>  </td> <td>  </td> <td colspan="2"></td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="6"> Options Outstanding</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="6"> Options Exercisable</td> <td>  </td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Exercise Price</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Number Outstanding</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Weighted Average Remaining Contractual Life</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Weighted Average Exercise Price </td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Number Exercisable</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Weighted Average Exercise Price</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:14%;"> 0.05</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:14%;vertical-align:bottom;"> 3,000,000</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:14%;vertical-align:bottom;"> 4.25</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:14%;vertical-align:bottom;"> 0.05</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:14%;vertical-align:bottom;"> 3,000,000</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:13%;vertical-align:bottom;"> 0.05</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> $</td> <td> 0.06</td> <td>  </td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> 5,000,000</td> <td>  </td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> 4.35</td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> $</td> <td style="vertical-align:bottom;"> 0.06</td> <td>  </td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> 5,000,000</td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> $</td> <td style="vertical-align:bottom;"> 0.06</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> $</td> <td> 0.07</td> <td>  </td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> 6,000,000</td> <td>  </td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> 0.35</td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> $</td> <td style="vertical-align:bottom;"> 0.07</td> <td>  </td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> 6,000,000</td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> $</td> <td style="vertical-align:bottom;"> 0.07</td> <td>  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> $</td> <td> 0.14</td> <td>  </td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> 3,000,000</td> <td>  </td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> 3.25</td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> $</td> <td style="vertical-align:bottom;"> 0.14</td> <td>  </td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> 3,000,000</td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> $</td> <td style="vertical-align:bottom;"> 0.14</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> $</td> <td> 0.02</td> <td>  </td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> 15,500,000</td> <td>  </td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> 9.30</td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> $</td> <td style="vertical-align:bottom;"> 0.02</td> <td>  </td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> 15,500,000</td> <td>  </td> <td>  </td> <td style="vertical-align:bottom;"> $</td> <td style="vertical-align:bottom;"> 0.02</td> <td>  </td></tr></table></div> -533000

5875000

6199000

5875000

6199000

0 11456917

570737981

549364626

52516508

305000

P10Y

300000

250000

143000

250000

P3Y

900000

P10Y

1200000 1200000

31697917

10000

33000

2000000

P10Y

5875000 324000 6199000 0.12 324000 52516508

6199000

150000

-40000 1000000

2000

50000

2000000

4000

100000

0.015 0.015

0.1

2022-10-17

18500000

15000000

-1000000

32500000 P2Y10M2D P9Y3M18D P5Y10M13D 0.07

0.02

0.07 0.06 18500000 15000000 0 32500000 1295000 300000 1595000

3000000

5000000

6000000

15500000

P4Y5M30D

P4Y4M6D

P4M6D

P3Y2M30D

P9Y3M18D

0.05

0.06

0.07

0.14

0.02

3000000

0.05

5000000

0.06

6000000

3000000

15500000

0.02

15000000

0.0154 32500000 32500000 1595000

0.1 0.05

247000

633000

55000

EX-101.SCH 5 mhtx-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - CAPITAL TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - LICENSE AGREEMENT link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - COMMITMENTS AND CONTIGENCIES link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - CAPITAL TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - CAPITAL TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - CAPITAL TRANSACTIONS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - CAPITAL TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - LICENSE AGREEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 mhtx-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity Interactive Data Current CONDENSED CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Class of Stock [Axis] Class A Convertible Preferred Stock [Member] Class B Convertible Preferred Stock [Member] Class C Redeemable Convertible Preferred Stock [Member] ASSETS Current assets: Cash and cash equivalents Prepaid expenses Due from the sale of assets - current portion Total current assets [Assets, Current] Investment in equity securities Property and equipment, net Due from the sale of assets Other assets Total assets [Assets] LIABILITIES Current liabilities: Accounts payable and accrued expenses Accrued expenses - related parties Total current liabilities [Liabilities, Current] Long-term liabilities: Notes payable, net of discounts Total long-term liabilities [Liabilities, Noncurrent] Total liabilities [Liabilities] Commitments and Contingencies - Note 7 Series D convertible preferred mandatory redeemable, authorized 105,761 shares, 105,761 and 105,761 shares issued and outstanding, respectively STOCKHOLDERS' EQUITY Capital stock $.001 par value Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively Common, authorized 950,000,000 shares, 559,281,064 and 559,281,064 shares issued, and outstanding, respectively Additional paid-in-capital Accumulated deficit Total stockholders' equity TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY [Liabilities and Equity] Series D convertible preferred Stock [Member] Capital stock, shares par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Revenue Operating costs: General and administrative expenses Research and development Total operating costs and expenses [Operating Costs and Expenses] Loss from operations before other income and expenses [Loss from operations before other income and expenses] Other income and (expenses): Gain (Loss) on fair value adjustment of investments Interest expense [Interest Expense] Total other income (expense) [Nonoperating Income (Expense)] NET INCOME (LOSS) [Net Income (Loss) Attributable to Parent] INCOME (LOSS) PER COMMON SHARE: Weighted average number of common shares outstanding (Basic) Basic income (loss) per common share Weighted average number of common shares outstanding (Diluted) Diluted income (loss) per common share CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Statement Equity Components [Axis] Preferred Stock Series B Common Stock Additional Paid-In Capital Accumulated Deficit Balance, shares [Shares, Issued] Balance, amount Net loss Balance, shares Balance, amount CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) CASH FLOWS FROM OPERATING ACTIVITIES: Net income (loss) Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation and amortization Loss (Gain) on fair value adjustment of investments Amortization of debt discount Changes in: Prepaid expenses [Increase (Decrease) in Prepaid Expense] Accounts payable and accrued expenses [Increase (Decrease) in Accounts Payable and Accrued Liabilities] Accounts payable and accrued expenses - related party Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of fixed assets Proceeds from sale of investments Net cash provided by (used in) investing activities [Net Cash Provided by (Used in) Investing Activities] CASH FLOWS FROM FINANCING ACTIVITIES: Net cash provided by financing activities NET DECREASE IN CASH [Cash, Period Increase (Decrease)] CASH, BEGINNING OF PERIOD CASH, END OF PERIOD SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid Income taxes paid BASIS OF PRESENTATION NOTE 1 - BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS INVESTMENT IN IMAGION BIOSYSTEMS NOTE 3 - INVESTMENT IN IMAGION BIOSYSTEMS NOTES PAYABLE NOTE 4 - NOTES PAYABLE CAPITAL TRANSACTIONS NOTE 5 - CAPITAL TRANSACTIONS LICENSE AGREEMENT NOTE 6 - LICENSE AGREEMENT COMMITMENTS AND CONTIGENCIES NOTE 7 - COMMITMENTS AND CONTIGENCIES RELATED PARTY TRANSACTIONS NOTE 8 - RELATED PARTY TRANSACTIONS SUBSEQUENT EVENTS NOTE 9 - SUBSEQUENT EVENTS BASIS OF CONSOLIDATION USE OF ESTIMATES CASH AND CASH EQUIVALENTS CASH CONCENTRATION PROPERTY AND EQUIPMENT INTANGIBLE ASSETS DUE FROM THE SALE OF ASSETS MARKETABLE SECURITIES REVENUE RECOGNITION FAIR VALUE OF FINANCIAL INSTRUMENTS LEASES INCOME TAXES BASIC AND DILUTED EARNINGS (LOSS) PER SHARE STOCK-BASED COMPENSATION RECENT ACCOUNTING PRONOUNCEMENTS Schedule of fair value measurement of assets and liabilities Schedule of basic and diluted earnings (loss) per share Schedule of changes to the investment in Imagion NOTES PAYABLE (Tables) Schedule of debt discount Summary of Company's stock option activity Exercise prices and weighted-average contractual lives of stock options outstanding BASIS OF PRESENTATION (Details Narrative) Accumulated deficit Working capital deficit SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) Fair Value By Asset Class Axis Fair Value By Fair Value Hierarchy Level Axis Total fair value [Member] Quoted prices in active markets for identical assets [Member] (Level 1) [Member] Significant other observable inputs [Member] (Level 2) [Member] Significant unobservable inputs [Member] (Level 3) [Member] Investment in equity securities Numerator: Denominator: Weighted-average basic shares outstanding Effect of dilutive securities Weighted-average diluted shares Basic earnings (loss) per share Diluted earnings (loss) per share Plan Name Axis Related Party Transactions By Related Party Axis Award Date [Axis] Range [Axis] Patent license agreement [Member] Los Alamos National Security LLC [Member] In 2008 [Member] Minimum [Member] Maximum [Member] In 2009 [Member] Antidilutive securities excluded from computation of earnings per share amount Proceeds from sale of assets held for sale Proceeds payable from sale of assets held for sale EX-101.CAL 7 mhtx-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 8 mhtx-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 9 mhtx-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2021	May 12, 2021
Cover [Abstract]
Entity Registrant Name	MANHATTAN SCIENTIFICS INC
Entity Central Index Key	0001099132
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Entity Common Stock Shares Outstanding		559,281,064
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

XML 11 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 254,000	$ 353,000
Prepaid expenses	17,000	12,000
Due from the sale of assets - current portion	300,000	300,000
Total current assets	571,000	665,000
Investment in equity securities	6,199,000	5,875,000
Property and equipment, net	8,000	6,000
Due from the sale of assets	300,000	300,000
Other assets	2,000	2,000
Total assets	7,080,000	6,848,000
Current liabilities:
Accounts payable and accrued expenses	169,000	159,000
Accrued expenses - related parties	935,000	853,000
Total current liabilities	1,104,000	1,012,000
Long-term liabilities:
Notes payable, net of discounts	110,000	104,000
Total long-term liabilities	110,000	104,000
Total liabilities	1,214,000	1,116,000
Commitments and Contingencies - Note 7	0	0
Series D convertible preferred mandatory redeemable, authorized 105,761 shares, 105,761 and 105,761 shares issued and outstanding, respectively	1,058,000	1,058,000
STOCKHOLDERS' EQUITY
Capital stock $.001 par value	0	0
Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively	0	0
Common, authorized 950,000,000 shares, 559,281,064 and 559,281,064 shares issued, and outstanding, respectively	559,000	559,000
Additional paid-in-capital	68,996,000	68,996,000
Accumulated deficit	(64,747,000)	(64,881,000)
Total stockholders' equity	4,808,000	4,674,000
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY	7,080,000	6,848,000
Class A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY
Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively	0	0
Class B Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY
Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively	0	0
Class C Redeemable Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY
Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively	$ 0	$ 0

XML 12 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Capital stock, shares par value	$ .001	$ .001
Preferred stock, shares authorized	447,804	447,804
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	950,000,000	950,000,000
Common stock, shares issued	559,281,064	559,281,064
Common stock, shares outstanding	559,281,064	559,281,064
Class A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	182,525	182,525
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Class B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	250,000	250,000
Preferred stock, shares issued	49,999	49,999
Preferred stock, shares outstanding	49,999	49,999
Class C Redeemable Convertible Preferred Stock [Member]
Preferred stock, shares authorized	14,000	14,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series D convertible preferred Stock [Member]
Preferred stock, shares authorized	105,761	105,761
Preferred stock, shares issued	105,761	105,761
Preferred stock, shares outstanding	105,761	105,761

XML 13 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
Revenue	$ 0	$ 0
Operating costs:
General and administrative expenses	181,000	169,000
Research and development	3,000	3,000
Total operating costs and expenses	184,000	172,000
Loss from operations before other income and expenses	(184,000)	(172,000)
Other income and (expenses):
Gain (Loss) on fair value adjustment of investments	324,000	(553,000)
Interest expense	(6,000)	(7,000)
Total other income (expense)	318,000	(560,000)
NET INCOME (LOSS)	$ 134,000	$ (732,000)
INCOME (LOSS) PER COMMON SHARE:
Weighted average number of common shares outstanding (Basic)	559,281,064	557,781,064
Basic income (loss) per common share	$ 0.00	$ (0.00)
Weighted average number of common shares outstanding (Diluted)	570,737,981	557,781,064
Diluted income (loss) per common share	$ 0.00	$ (0.00)

XML 14 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)	Total	Preferred Stock Series B	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Dec. 31, 2019		49,999	557,781,064
Balance, amount at Dec. 31, 2019	$ (1,005,000)	$ 0	$ 558,000	$ 67,632,000	$ (69,195,000)
Net loss	(732,000)	$ 0	$ 0	0	(732,000)
Balance, shares at Mar. 31, 2020		49,999	557,781,064
Balance, amount at Mar. 31, 2020	(1,737,000)	$ 0	$ 558,000	67,632,000	(69,927,000)
Balance, shares at Dec. 31, 2020		49,999	559,281,064
Balance, amount at Dec. 31, 2020	4,674,000	$ 0	$ 559,000	68,996,000	(64,881,000)
Net loss	134,000				134,000
Balance, shares at Mar. 31, 2021		49,999	559,281,064
Balance, amount at Mar. 31, 2021	$ 4,808,000	$ 0	$ 559,000	$ 68,996,000	$ (64,747,000)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 15 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 134,000	$ (732,000)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	1,000	0
Loss (Gain) on fair value adjustment of investments	(324,000)	553,000
Amortization of debt discount	6,000	7,000
Changes in:
Prepaid expenses	(5,000)	(5,000)
Accounts payable and accrued expenses	10,000	77,000
Accounts payable and accrued expenses - related party	82,000	0
Net cash used in operating activities	(96,000)	(100,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(3,000)	(4,000)
Proceeds from sale of investments	0	84,000
Net cash provided by (used in) investing activities	(3,000)	80,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Net cash provided by financing activities	0	0
NET DECREASE IN CASH	(99,000)	(20,000)
CASH, BEGINNING OF PERIOD	353,000	261,000
CASH, END OF PERIOD	254,000	241,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	0	0
Income taxes paid	$ 0	$ 0

XML 16 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION	3 Months Ended
BASIS OF PRESENTATION	Mar. 31, 2021
BASIS OF PRESENTATION
NOTE 1 - BASIS OF PRESENTATION	The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2020, filed on April 15, 2021. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented. Operating results for the three months period ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements. As of March 31, 2021, the Company has an accumulated deficit of $64,747,000 and negative working capital of $533,000. Because of these conditions, the Company will require additional working capital to develop business operations. The Company intends to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations. As of the filing date, the Coronavirus (“COVID-19”) has caused significant volatility in global markets, including the market price of our securities. The demand for our products and services has decreased and the ability of our customers to make payments for the products and services they purchased has been negatively impacted. These factors raise substantial doubt about the Company’s ability to continue within one year from the date of filing. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. The ability to continue as a going concern is dependent on out generating cash from the sale of our common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plan includes selling our equity securities and/or obtaining debt financing to fund our capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

XML 17 R8.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

3 Months Ended

Mar. 31, 2021

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION:

USE OF ESTIMATES:

CASH AND CASH EQUIVALENTS:

CASH CONCENTRATION:

PROPERTY AND EQUIPMENT:

INTANGIBLE ASSETS:

License Agreements

DUE FROM THE SALE OF ASSETS:

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

MARKETABLE SECURITIES:

REVENUE RECOGNITION:

FAIR VALUE OF FINANCIAL INSTRUMENTS:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Our financial assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2020 and December 31, 2020, consisted of the following:

	Total fair value at March 31, 2021		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	6,199,000	$	6,199,000	$	-	$	-

	Total fair value at December 31, 2020		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	5,875,000	$	5,875,000	$	-	$	-

LEASES

During June 2019, the Company entered into an assignment and assumption of lease with the landlord and another entity for the lease term through April 2021.

INCOME TAXES

BASIC AND DILUTED EARNINGS (LOSS) PER SHARE

The following table shows the computation of basic and diluted earnings (loss) per share for the three months ended March 31, 2021 and 2020:

	Three Months Ended
	March 31, 2021		March 31, 2020
Numerator:
Net income (loss)	$	134,000	$	(732,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064		557,781,064
Effect of dilutive securities		11,456,917		-
Weighted-average diluted shares		570,737,981		549,364,626

Basic earnings (loss) per share	$	0.00	$	(0.00	)
Diluted earnings (loss) per share	$	0.00	$	(0.00	)

STOCK BASED COMPENSATION

RECENT ACCOUNTING PRONOUNCEMENTS

The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Company’s results of operations, financial position or cash flow.

The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.

XML 18 R9.htm IDEA: XBRL DOCUMENT

INVESTMENT IN IMAGION BIOSYSTEMS

3 Months Ended

Mar. 31, 2021

INVESTMENT IN IMAGION BIOSYSTEMS

NOTE 3 - INVESTMENT IN IMAGION BIOSYSTEMS

Below is reconciliation for the changes to the investment in Imagion for the three months ended March 31, 2020:

Balance as of December 31, 2020	$	5,875,000
Change in the unrealized fair value of securities		324,000
Balance as of March 31, 2021	$	6,199,000

XML 19 R10.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

3 Months Ended

Mar. 31, 2021

NOTES PAYABLE

NOTE 4 - NOTES PAYABLE

Notes payable	$	150,000
Less: Discounts on notes payable		(40,000	)
Notes payable, net of discounts	$	110,000

XML 20 R11.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS

3 Months Ended

Mar. 31, 2021

CAPITAL TRANSACTIONS

NOTE 5 - CAPITAL TRANSACTIONS

Stock Activity

During the three months ended March 31, 2021, the Company had not issued common stock.

Options

At March 31, 2021, the 32,500,000 outstanding options had an aggregate intrinsic value of $1,595,000. A summary of the Company’s stock option activity and related information is as follows:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Life		Number of Options Exercisable		Aggregate Intrinsic Value
Outstanding as of December 31, 2020		18,500,000		$	0.07		2.84		18,500,000	$	1,295,000
Granted		15,000,000			0.02		9.30		15,000,000		300,000
Exercised		-			-		-		-
Expired		(1,000,000	)		0.06		-		-
Outstanding as of March 31, 2021		32,500,000		$	0.07		5.87		32,500,000	$	1,595,000

Exercise prices and weighted-average contractual lives of 32,500,000 stock options outstanding as of March 31, 2021 are as follows:

				Options Outstanding				Options Exercisable
Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	0.05		3,000,000		4.25	$	0.05		3,000,000	$	0.05
$	0.06		5,000,000		4.35	$	0.06		5,000,000	$	0.06
$	0.07		6,000,000		0.35	$	0.07		6,000,000	$	0.07
$	0.14		3,000,000		3.25	$	0.14		3,000,000	$	0.14
$	0.02		15,500,000		9.30	$	0.02		15,500,000	$	0.02

The fair value for options granted were determined using the Black-Scholes option-pricing model.

The Company did not recognize compensation expense During the three months ended March 31, 2021.

XML 21 R12.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENT	3 Months Ended
LICENSE AGREEMENT	Mar. 31, 2021
LICENSE AGREEMENT
NOTE 6 - LICENSE AGREEMENT	On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products. During the three months ended March 31, 2021, the Company received $0 as a minimum royalty payment.

XML 22 R13.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTIGENCIES	3 Months Ended
COMMITMENTS AND CONTIGENCIES	Mar. 31, 2021
COMMITMENTS AND CONTIGENCIES
NOTE 7 - COMMITMENTS AND CONTIGENCIES	Legal matter contingencies The Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company. Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted. Once established, such provisions are adjusted when there is more information available of when an event occurs requiring a change.

XML 23 R14.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS	3 Months Ended
RELATED PARTY TRANSACTIONS	Mar. 31, 2021
RELATED PARTY TRANSACTIONS
NOTE 8 - RELATED PARTY TRANSACTIONS	As of March 31, 2021 and December 31, 2020, the Company had accrued expenses to related parties of approximately $935,000 and $853,000. As of March 31, 2021, the amounts are due to the Company’s sole officer for compensation $247,000 and the chairman of the board for compensation of $633,000 and the members of the board of directors of $55,000.

XML 24 R15.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS	3 Months Ended
SUBSEQUENT EVENTS	Mar. 31, 2021
SUBSEQUENT EVENTS
NOTE 9 - SUBSEQUENT EVENTS	In accordance with ASC 855-10, the Company has analyzed its operations subsequent to March 31, 2021 to the date these financial statements were issued, and there were no other material subsequent events to disclose in these financial statements, except as noted.

XML 25 R16.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies)

3 Months Ended

Mar. 31, 2021

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION

USE OF ESTIMATES

CASH AND CASH EQUIVALENTS

CASH CONCENTRATION

PROPERTY AND EQUIPMENT

INTANGIBLE ASSETS

License Agreements

DUE FROM THE SALE OF ASSETS

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

MARKETABLE SECURITIES

REVENUE RECOGNITION

FAIR VALUE OF FINANCIAL INSTRUMENTS

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Our financial assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2020 and December 31, 2020, consisted of the following:

	Total fair value at March 31, 2021		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	6,199,000	$	6,199,000	$	-	$	-

	Total fair value at December 31, 2020		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	5,875,000	$	5,875,000	$	-	$	-

LEASES

During June 2019, the Company entered into an assignment and assumption of lease with the landlord and another entity for the lease term through April 2021.

INCOME TAXES

BASIC AND DILUTED EARNINGS (LOSS) PER SHARE

The following table shows the computation of basic and diluted earnings (loss) per share for the three months ended March 31, 2021 and 2020:

	Three Months Ended
	March 31, 2021		March 31, 2020
Numerator:
Net income (loss)	$	134,000	$	(732,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064		557,781,064
Effect of dilutive securities		11,456,917		-
Weighted-average diluted shares		570,737,981		549,364,626

Basic earnings (loss) per share	$	0.00	$	(0.00	)
Diluted earnings (loss) per share	$	0.00	$	(0.00	)

STOCK-BASED COMPENSATION

RECENT ACCOUNTING PRONOUNCEMENTS

The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Company’s results of operations, financial position or cash flow.

The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.

XML 26 R17.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables)

3 Months Ended

Mar. 31, 2021

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

Schedule of fair value measurement of assets and liabilities

	Total fair value at March 31, 2021		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	6,199,000	$	6,199,000	$	-	$	-

	Total fair value at December 31, 2020		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	5,875,000	$	5,875,000	$	-	$	-

Schedule of basic and diluted earnings (loss) per share

	Three Months Ended
	March 31, 2021		March 31, 2020
Numerator:
Net income (loss)	$	134,000	$	(732,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064		557,781,064
Effect of dilutive securities		11,456,917		-
Weighted-average diluted shares		570,737,981		549,364,626

Basic earnings (loss) per share	$	0.00	$	(0.00	)
Diluted earnings (loss) per share	$	0.00	$	(0.00	)

XML 27 R18.htm IDEA: XBRL DOCUMENT

INVESTMENT IN IMAGION BIOSYSTEMS (Tables)

3 Months Ended

Mar. 31, 2021

INVESTMENT IN IMAGION BIOSYSTEMS

Schedule of changes to the investment in Imagion

Balance as of December 31, 2020	$	5,875,000
Change in the unrealized fair value of securities		324,000
Balance as of March 31, 2021	$	6,199,000

XML 28 R19.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Tables)

3 Months Ended

Mar. 31, 2021

NOTES PAYABLE (Tables)

Schedule of debt discount

Notes payable	$	150,000
Less: Discounts on notes payable		(40,000	)
Notes payable, net of discounts	$	110,000

XML 29 R20.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS (Tables)

3 Months Ended

Mar. 31, 2021

CAPITAL TRANSACTIONS

Summary of Company's stock option activity

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Life		Number of Options Exercisable		Aggregate Intrinsic Value
Outstanding as of December 31, 2020		18,500,000		$	0.07		2.84		18,500,000	$	1,295,000
Granted		15,000,000			0.02		9.30		15,000,000		300,000
Exercised		-			-		-		-
Expired		(1,000,000	)		0.06		-		-
Outstanding as of March 31, 2021		32,500,000		$	0.07		5.87		32,500,000	$	1,595,000

Exercise prices and weighted-average contractual lives of stock options outstanding

				Options Outstanding				Options Exercisable
Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	0.05		3,000,000		4.25	$	0.05		3,000,000	$	0.05
$	0.06		5,000,000		4.35	$	0.06		5,000,000	$	0.06
$	0.07		6,000,000		0.35	$	0.07		6,000,000	$	0.07
$	0.14		3,000,000		3.25	$	0.14		3,000,000	$	0.14
$	0.02		15,500,000		9.30	$	0.02		15,500,000	$	0.02

XML 30 R21.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Details Narrative) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
BASIS OF PRESENTATION (Details Narrative)
Accumulated deficit	$ (64,747,000)	$ (64,881,000)
Working capital deficit	$ (533,000)

XML 31 R22.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Investment in equity securities	$ 6,199,000	$ 5,875,000
Total fair value [Member]
Investment in equity securities	6,199,000	5,875,000
Quoted prices in active markets for identical assets [Member] \| (Level 1) [Member]
Investment in equity securities	6,199,000	5,875,000
Significant other observable inputs [Member] \| (Level 2) [Member]
Investment in equity securities	0	0
Significant unobservable inputs [Member] \| (Level 3) [Member]
Investment in equity securities	$ 0	$ 0

XML 32 R23.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Numerator:
Net income (loss)	$ 134,000	$ (732,000)
Denominator:
Weighted-average basic shares outstanding	559,281,064	557,781,064
Effect of dilutive securities	11,456,917	0
Weighted-average diluted shares	570,737,981	549,364,626
Basic earnings (loss) per share	$ 0.00	$ (0.00)
Diluted earnings (loss) per share	$ 0.00	$ (0.00)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 33 R24.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	May 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Antidilutive securities excluded from computation of earnings per share amount		52,516,508
Proceeds from sale of assets held for sale	$ 300,000	$ 300,000			$ 300,000
Proceeds payable from sale of assets held for sale		300,000
Cash FDIC insured amount		250,000		$ 250,000
Cash exceeding insured amount		$ 0		$ 143,000	0
Remaining amount of assets					900,000
Adjusted asset valuation						$ 1,200,000
Sale of asset					$ 1,200,000
Weighted average number diluted shares		0	31,697,917
Minimum [Member]
Property and equipment useful lives		3 years
Maximum [Member]
Property and equipment useful lives		10 years
Patent license agreement [Member] \| Los Alamos National Security LLC [Member] \| In 2008 [Member]
Fair value of common stock issued		$ 305,000
Amortization period		10 years
Patent license agreement [Member] \| Los Alamos National Security LLC [Member] \| In 2009 [Member]
Fair value of common stock issued		$ 33,000
Amortization period		10 years
Annual license fee		$ 10,000
Common stock issued		2,000,000

XML 34 R25.htm IDEA: XBRL DOCUMENT

INVESTMENT IN IMAGION BIOSYSTEMS (Details)	3 Months Ended
INVESTMENT IN IMAGION BIOSYSTEMS (Details)	Mar. 31, 2021 USD ($)
INVESTMENT IN IMAGION BIOSYSTEMS
Balance as of December 31, 2020	$ 5,875,000
Change in the realized fair value of securities	324,000
Balance as of March 31, 2021	$ 6,199,000

XML 35 R26.htm IDEA: XBRL DOCUMENT

INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Fair value of investment	$ 6,199,000	$ 5,875,000
Imagion Biosystems, Inc. [Member]
Trading price per share	$ 0.12
Change in unrealized gain in investment	$ 324,000
Common stock owned shares	52,516,508
Fair value of investment	$ 6,199,000

XML 36 R27.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
NOTES PAYABLE
Notes payable	$ 150,000
Less: Discounts on notes payable	(40,000)
Notes payable, net of discounts	$ 110,000	$ 104,000

XML 37 R28.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Oct. 17, 2019	Mar. 31, 2021	Mar. 31, 2020
Amortization of debt discount		$ 6,000	$ 7,000
Individuals [Member]
Shares issued in advance for debt	1,000,000
Amortization of debt discount		2,000
Secured note	$ 50,000
Price per share	$ 0.015
Interest rate	10.00%
Debt due date	Oct. 17, 2022
Related Party [Member]
Shares issued in advance for debt	2,000,000
Amortization of debt discount		$ 4,000
Secured note	$ 100,000
Price per share	$ 0.015
Interest rate	10.00%
Debt due date	Oct. 17, 2022

XML 38 R29.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS (Details) - USD ($)	1 Months Ended	3 Months Ended
CAPITAL TRANSACTIONS (Details) - USD ($)	Mar. 22, 2021	Mar. 31, 2021
CAPITAL TRANSACTIONS
Number of Options, Outstanding Beginning Balance		18,500,000
Number of Options, Granted	15,000,000	15,000,000
Number of Options, Expired		(1,000,000)
Number of Options, Outstanding Ending Balance		32,500,000
Weighted Average Life
Weighted Average Life, Outstanding Beginning Balance		2 years 10 months 2 days
Weighted Average Life, Granted		9 years 3 months 18 days
Weighted Average Life, Outstanding Ending Balance		5 years 10 months 13 days
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning		$ 0.07
Weighted Average Exercise Price, Granted		0.02
Weighted Average Exercise Price, outstanding ending balance		0.07
Weighted Average Exercise Price, Expired		$ 0.06
Number of Options Exercisable
Number of Options Exercisable,Outstanding Beginning Balance		18,500,000
Number of Options Exercisable, Granted		15,000,000
Number of Options Exercisable, Expired		0
Number of Options Exercisable,Outstanding Ending Balance		32,500,000
Aggregate intrinsic value
Aggregate intrinsic value, beginning		$ 1,295,000
Aggregate intrinsic value, granted		300,000
Aggregate intrinsic value, outstanding		$ 1,595,000

XML 39 R30.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS (Details 1)	12 Months Ended
CAPITAL TRANSACTIONS (Details 1)	Dec. 31, 2020 $ / shares shares
Exercise Price 0.05 [Member]
Number of Options, Outstanding Beginning Balance \| shares	3,000,000
Weighted Average Remaining Contractual Life	4 years 5 months 30 days
Weighted Average Exercise Price \| $ / shares	$ 0.05
Number of Options Exercisable, Outstanding Beginning Balance \| shares	3,000,000
Weighted Average Exercise Price, exercisable \| $ / shares	$ 0.05
Exercise Price 0.06 [Member]
Number of Options, Outstanding Beginning Balance \| shares	5,000,000
Weighted Average Remaining Contractual Life	4 years 4 months 6 days
Weighted Average Exercise Price \| $ / shares	$ 0.06
Number of Options Exercisable, Outstanding Beginning Balance \| shares	5,000,000
Weighted Average Exercise Price, exercisable \| $ / shares	$ 0.06
Exercise Price 0.07 [Member]
Number of Options, Outstanding Beginning Balance \| shares	6,000,000
Weighted Average Remaining Contractual Life	4 months 6 days
Weighted Average Exercise Price \| $ / shares	$ 0.07
Number of Options Exercisable, Outstanding Beginning Balance \| shares	6,000,000
Weighted Average Exercise Price, exercisable \| $ / shares	$ 0.07
Exercise Price 0.02 [Member]
Number of Options, Outstanding Beginning Balance \| shares	15,500,000
Weighted Average Remaining Contractual Life	9 years 3 months 18 days
Weighted Average Exercise Price \| $ / shares	$ 0.02
Number of Options Exercisable, Outstanding Beginning Balance \| shares	15,500,000
Weighted Average Exercise Price, exercisable \| $ / shares	$ 0.02
Exercise Price 0.14 [Member]
Number of Options, Outstanding Beginning Balance \| shares	3,000,000
Weighted Average Remaining Contractual Life	3 years 2 months 30 days
Weighted Average Exercise Price \| $ / shares	$ 0.14
Number of Options Exercisable, Outstanding Beginning Balance \| shares	3,000,000
Weighted Average Exercise Price, exercisable \| $ / shares	$ 0.14

XML 40 R31.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
CAPITAL TRANSACTIONS (Details Narrative) - USD ($)	Mar. 22, 2021	Mar. 31, 2021
Options to purchase	15,000,000
Number of Options, Granted	15,000,000	15,000,000
Weighted average contractual lives, stock options outstanding		32,500,000
Number of Options, Outstanding Balance		32,500,000
Aggregate intrinsic value		$ 1,595,000
October 1, 2020 [Member]
Closing market price of common stock		$ 0.0154

XML 41 R32.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENT (Details Narrative)	3 Months Ended
LICENSE AGREEMENT (Details Narrative)	Mar. 31, 2021 USD ($)
LICENSE AGREEMENT
Minimum Royalty Payment	$ 0
Royalty percentage on dental products	10.00%
Royalty percentage on other licensed products	5.00%

XML 42 R33.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Accrued expenses - related parties	$ 935,000	$ 853,000
Sole Officer [Member]
Accrued expenses - related parties	247,000
Chairman [Member]
Accrued expenses - related parties	633,000
Board of Director [Member]
Accrued expenses - related parties	$ 55,000

EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( UGL5('04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " -9[%2!824*>\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*$YI"R;UI:.G#@8K;.QF;+4UBQ-C:R1]^SE>FS*V!]C1TN]/ MGT"-]D+W 9]#[S&0Q?@PNK:+0OL-.Q-Y 1#U&9V*94ITJ7GL@U.4GN$$7ND/ M=4*HJVH%#DD910HF8.%G(I.-T4('5-2'*][H&>\_0YMA1@.VZ+"C"+SDP.0T MT5_&MH$[8((1!A>_"VAF8J[^BT@BX>-^PV^76Q?3SLF*RKFA?5LN#K Z_%%W%W:]L4?[ MCXUO@K*!7WQ4IE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" -9[%2CXG\LLP# 8#@ & 'AL+W=O-NYY.W&R][$S4G*G,7,M#V*Q8R7*DL9?11(EGE.Q/&.9OPP M=[!S:GA*]XG2#>YB5I ]W5+U9_$HH.8V+'&:4R93SI"@N[FSQ%]#W], ,^*O ME![D61GIJ;QR_J8KZWCN>%H1S6BD- 6!OW<:TBS33*#COYK4:;ZI@>?E$_O* M3!XF\THD#7GV=QJK9.[<.BBF.U)FZHD?OM-Z0F/-%_%,FE]TJ,8&4P=%I50\ MK\&@($]9]4\^ZD"< ?S)!8!? _R? #BX AJ0& F6BDST_I&%%G,!#\@H4<# MFRZ8V!@TS"9E>AFW2D!O"CBU"/D[%6B$9$($E3-7 :?N<:,:?U?A_0OX #UP MIA*)[EE,X\]X%[0T@OR3H#O?2OA Q!4*\*_(]WS,Y6J(WJB^U23,H4V)*==D;?S/"PW MWY?/S\L-VH;K^\WS>K4.MVB]"2T:QXW&\1"-(66@,$-K6-L/]#L]=JFT,WF> MA[WI% >^1=:DD36QDGWC40D6HM#SL>B,F!V.O=$/BXJ;1L6-E68)$F(C8Y61 M?9<,.WY',DDM.FX;';=6GK 4PJA(902+]$*)T*<0@0]T!L?.-AIA?Q38SLRT MT34=LGFV.@D.<%89T;N8>F;]GP MF>7B(8+N:7XKS1]T\.NM]40++I36N%5$E=WW@YWQ MY>=;Y;.RUHAQ,.SL/U*1\MBZTWNH3E?,+U^^]%P3N#5U/,C55VD&]T4(NO9< M="^EG6?#V8A$$:0Y DCBBM"FL+5T;'?B)H"U7]1Q7$%S][K:Z58O-E6MH^.! MEG[N8I&RWZ-,QX'D.J>96\>@-_$-G2.B/4DE%6 R'HBL[J8G' MAECGT.^+\7CJWV)OA@O&)E[EGMK M0S=/$HDB7C)5I>%-:_/L69IDWVV'5V\F\"6X#R3*Z Z@WM4-[")1/4.JBN*% MR>1?N8)W@2DF\'2C0@^ _AWGZE31'V@>@XO_ 5!+ P04 " -9[%2#!NN M9R4& ! &P & 'AL+W=ODDV:_?J2D2E9)T49; M%/N06"]WQ^=>>(].NGBF["/?8BS YRS-^65O*\3NS6# XRW.$#^G.YS+.QO* M,B3D*7L<\!W#*"F4LG3@.DXPR!#)>U<7Q;4[=G5!]R(E.;YC@.^S#+&7:YS2 MY\L>['VY<$\>MT)=&%Q=[- C7F'Q?G?'Y-F@MI*0#.>&;B1GRFBO7E,I M'AY_L?Y;X;QTY@%Q/*'IGR01V\M>U ,)WJ!]*N[I\UM<.>0K>S%->?$?/%>R M3@_$>RYH5BE+!!G)RU_TN0K$@0(<=BBXE8)[JH)7*7B%HR6RPJTI$NCJ@M%G MP)2TM*8.BM@4VM(;DJLTK@23=XG4$U>3V^5TMES-ID >K6X7\^EX+4^NQXOQ MSV7H%SL#[U13\\NK7BX&0BRK505PM<%TNX'8L<(/8.?!@'[B."PWJ M$[OZ%,>UNM-6'TA7:W_=VE^WL.=U^;MG#.<"(,ZQX&\L%KW:HE=8''991'P+ M4)Z 6!W@3WORA%*Y!#?%JC05%*;4#GNZ'X-S[?"F^XQV#": ;'%@,L8 M KJI\B0+,*X2MZ-,[7\3=E]#I6*F@3\JUD(?U.@#*_HU%2BM49:P32 #;74_ MA#I(72P(_$Z080TRM(*%6MAA4[3]!TKVEN)DEG@5>J'"[LZNF-2;7 'C 1/V$D6<%!;-G0B0_0, M@D$TC+HA-B0"3V.1E* 'DA9[QT8EL.$2:">3<1S3O>0.L$,OZ$%6D2I[%,=L MC^U]N[+;:LF!89N:Y/Q1=T@:;H%V$CH&_38*.A2)APS(PL%;>@N:/9P*S[.3: M:[@!VLEA206N"Z_HL*J')827)6D,B-[U(33M1(-<.VYMS T[0#L]E.E+34$Q MXM5;OQFO0)"N\1E'K;ARXTE9E!$,)N,G,;@G#M!#&A64:*!P5> MM* )S07)'W$>DV)KJUH!H0F\JY/"U["M(FW #6FX=M)88::034%,Y3..[#>J M>1?*0 =OQ\&$/ M8ICWZW/E M?/L>()RK1J?NR+F8"WD@0].7EOD.%U-I^F*,C$Y'TK+A^>0$P7:4#H8?.V^M MUK>3=V]O%]/9_>HUF/W^?K[^RS94-;SE'AN"=D15MIQ7XX_@U;GC0-7V@1R% M]M@8#)V'M##81-HX&Y9RCXY 946TDC\D?PL+FO4"-=U3F+?8[UN:)ICQ MU]5 :02M$ZI\$#?U/H-@$'93K]M0KWN$>F_7XP58S,?7\\5\/9^M^N!F]N'# M>#E?SJI6",;+*3C>(RN7=/(UCR$&0>L8XC4L[1UAZ51.26"LV+GFO+K#@571 MB_^^P=D#9O_8WG0U+.O!'\D?7D-,GOL_ZLL5&%M?MHJTG3QX47B$)(MT77]W MNAJV\X8_-%T-PWAVAOG)Z=))0DN73:3M9$,AGIU"RG1-P'W]Q/C=F6NXP M_ M:.::MNT=>Y_V4S,7:2^RM?-]2WI1O$'DG.08HW4LQ4L]G=9'6 P BQ( !@ !X;"]W;W)KO M#0S$@9B$[N9B@N&QG27%D(\?IVS$.$VLZSLZMV'1,#R(*$[)B@!_B&+,? MCR2BIXD%K=<3S^$^$.J$/1VG>$_61/R1KI@%#))[IZ3TI&O)4O2V->/87G/+8 M_L "VP,7-"Z2)4$<)ODW_EY,Q%D"=*\DH"(!W9K0*Q)Z6:,Y6=;6 @L\'3-Z M DQ%RVKJ()N;+%MV$R;J9UP+)J^&,D],YY^?%LNG]7(!Y-'Z\\ !OP0)[E8UM(#E7-WA;W?,SO MB:[<\Q-F#Z 'WP+D(-B0/C>G+\BV3'?T=%MV7TX!*J< 9?7<:U. TU#@",BY MWKZ\+;H"*6;@B*,#:>K/7/ ->'"$_Q&]J*J_I9375TW^0VN8ANR6R&XGY)#S0S.N6^-P+DA- M$1JD5T)ZG2#E\L@%3OPPV3>1>JVDI@B-M%^2]LV:IG$L%\E[?OY^C6'D.?GG M@O:62(UZ4%(/[J>^KH!!C ME=@C,W:$.06J/T['/S!'^QZM24=#TL!M#=-#*PJ#9.CJN3$55(ZTI1*>M[ F: M_2F7W^-/RZ\R%]C-75KD5S<0Y#6LA^UQ.G9E-[";WQCD5W<2=R0_E\1M83IP MY3K0;#M=95AWE$;JMC"=NG(=V&([F1SGX)GX1+XD*37^K#(K_X!F ^FHS+HS M0+=!F&UA.G3E'M!L'QUT.6I?:$PA^C_VE>V@;K;3HD=4]Y-+6F.(3ENY#3*[ MS9JP4,(MP/9,?>G]ZD-G;S[=;,.L/E2W!.AX@SZ\G*/6.!V[\@_4[?WFNOY0 M_:VE&;DU3D>N' AUX_3?\%4$L#!!0 ( M UGL5( \#T[+@0 .0. 8 >&PO=V]R:W-H965T&UL MK5==C]HX%/TK%MH'1MJ9Q D0& $2 W2+5& $S/;9$ /9)C%K&YC^^[UV(!!B M3%7M"XG#_3CG7MO';A\9_R&VE$KTF<2IZ%2V4NY>'4>LMC0AXH7M: K_K!E/ MB(0AWSABQRD)M5,2.Y[K-IR$1&FEV];?WGFWS?8RCE+ZSI'8)PGA/]]HS(Z= M"JZ3D4<(HH:F(6(HX77>I$%<.$,?LX)TNY-]1@\TW5-36S+'AG942_S0!;J'ZT+9+ IHZCF:NK46 MTQWE1$;I!JV8D.+50K"1AVQ8"?Y%4X@9(Y*&B(2P+"(A58X#1?03=CA!A8E\ M%K1^10TWL>O>5L!@UFA=FQ4P!SGFX$%3!"5\M=6@0^A0S':P'TH3T*"$P"_# M?&!4 -G,03:M(!=,0EE9L6,:L:VN34-=:V7 !K/ NPNYE4-N62%_8T*@-6?) M&39+!5I24#B*F-Q2CJ)TQ1+ZD$6K!._92,-D9^&!W _9PG] :]1T1&P-$ XT&QD+= MH5 &N^=Z_?XDQ=Z%B&-U#?!$-;%>-R7"!1I/^=#R$.3*=S\TPR_* ?5/O MRW;/@6]9)1/Q=(+F7WNSH76A7.0%V_7ENS[]41"7 VPI M&XK2?;*$1L+:@$XFL';$EL $1' P%A*6JMHKJV]$1"MSUG!JM)$>Y%B[!=C'ZO"X,H MWI?/42UGKZ@W'Q_4UQ4E[RC,RH P ^PT !@ !X;"]W;W)KKU$2J8%$$^U,DRGIKO:C"TZ#"CAKG&;VW^^%4#:) M3)869,E0N@A*RQKN,/]+]5](LR*[T8IJ5]6^T;[":@N)= MR6G>D,%!GA:'*_[9!'%$T,T.@M$0C#."87<0S(9@7CN#U1"L\QG<#H+=$.QS M0M>BG8;@U-D?PJJ3#C''XR&C>\0J-*A5-W6Y:C8$G!959T6'P<+![" MZ4,T#1'<18MO\_!^!8-H!9?OTX=5A!8S&"V"W[\NOH73Q^@3FOYXFJ_^0C?A M=#8/YJM;=/-4X%V26S=:R>9UEG--=P:^Q/#DH.D=F!KJFV9JFG;H.1. 9(A01MNT)0E,1YKB. M:0C F<2:X^O^B;>3G*PV)^MB3@_P/RBC92G+PQ**,W EY@*K-XY>Q%2WG=:R\ZN]W6=YXHCIZ:[IBL5T M>HLI(J2]+<[8T=L2:X[O&VYG:=TV)_<#VY:\M.Y5I151MNT;%TKKM9:]#VQ; M\M)ZHF7'M<3*>KV5%1&P++&RXH2.Y_N.6%D1.' L#V+JJJS?QN3_[UW+%R;5 M33&-62_LQ)BN_7Q4L?2BE'P! 21( !@ !X;"]W;W)KO7/R1&TH5>HNC1-ZT-DIMK]IM&6QH3.0%W]($OJRX MB(F"5[%NRZV@),RW2])6OJ4_6TG0MX:Y=10A;31#*>($%7-ZVQ=37!O=0A MLWAF]%4>/*,TE1?._Z0O;GC3ZJ2(:$0#E88@\+>G$QI%:23 \4\1M%7VF3H> M/G]$O\N2AV1>B*03'OUFH=K9-V3#DG08?27@*P,_-9K,O*GC^W"GXR6\^$OX>W2\ MI8]F=V@R]G^ANX?9;Q^=/25D%S)%PW/T$SWY4W3VU_EU6P&4-& [*+J]S;O% M#=W:Z)$G:B.1DX0T//9O0PIE'O@CCUML#/A(Q 6RK1$=["EP3/YNGO' ,'83K15C=XO9(YK-G<5XZ7KW:#Q9NL_NTG7\*T,_W;*?;M9/MZ$?#PJ= M)0&/*3J+N)3:HCRR[V^E GOM#ANIF/_LV/K0[@M@K(?:,5(S# MOV$:0^4KB12'T@]X$K"(HN0S]O1SVA@0N4$[24/XC&#!$D2Q9)U7/%.,2A-S MER6L2R-S4PK+7L!(OI@D(2(Q%XK]FS7H6,S#]0Y9K'-8-VI@KU_"[!MA/@ Q MZ.P>UN-S!$!7A FT)]&.(E+RBO@*F-K3@F4=^'X-UT\;:^9 W:[7LQNGP*!, M8F!,8GQ ;0HVI"\*A4P&?)T8,Y\+NB4L1/0-=%=2[=@4(8X&IU=/]Z39,<0# ;#,@Q-DPR#1EKR3 M%ZC+K!B"0.SH"=R6MB)JN.MF_>:!LG"%&_]_W*!1@D8$Y K,A'K7YH%K =8 MDT?=K"F'2B4L^^3R?7*UTV*VZY-AJ*D1G5TV2$W0*^&QNM]2.-=[=OQO*)Q5 MZ8?5,]?03@0;V*FE*\>*O0%11$JJ7^>*4,<+G886C5FWF91*4RRSJ,P%#R@- M)5H)'B-)(OJ%M=DRB4:!MVXR,."MQ,4RJTLY_[:"[QGLQ-#+.SHK)N-Y ?P+ MLU$G+QK6ZV8#PU2LU,4:?&LJWKG>V)M\8RI6ZF -O\_7BB4$=C2G61J>'F>3 MR?&^N)(@;)8@SUFBJ3-9.&/?@2K--O,Z>%BC+\-A?11U=KAY&'$E1-@L1"FP M'^C6N7<]+QT\.'C KMF=3;5HZZIB]S1S3F.'+ZUFM)7\8+/\Y&@=;WH"9UTU M<$^S\=+9=0TX*XG!YI.(_S2?/V1'N?$#FKK^Y&'F/RV(1#B@S MSU0HN%(';#Z7N(FB M8.E.Y^M+QT3Q:#T>085Z4EV*PE;G[>4.2-RF9LO=I) MJ(;-9))C:Q$Q]KBA)*0B-8#O*\[5QTO:07E[ M-/H/4$L#!!0 ( UGL5)XT4\;-P< !02 8 >&PO=V]R:W-H965T M&ULI5AM3^0X$OXK5M_J="?U]!O,SNP.( '#:M%IAMEI=N^^ MNI-*XL6QL[;33?_[>\I.0H &H;LOD!=7U5-/O:9/=M;=^8HHB/M:&W\ZJ4)H M?I[/?591+?W,-F3PIK"NE@&WKIS[QI',HU"MYZO%XL=Y+969G)W$9]_GD?/GSQ3&?CP?^4+3SHVO!GFRLO>.;Z_QTLF! I"D+K$'BWY8N26M6 M!!A_=3HG@TD6'%_WVG^)OL.7C?1T:?6_51ZJT\G'B<_Z M,JM]_"MVZ>P1+&:M#[;NA'%?*Y/^R_N.AY' Q\4+ JM.8!5Q)T,1Y6<9Y-F) MLSOA^#2T\45T-4H#G#(*L@%\XNSM?7:W'SB_CV_6I]]?7V_/;ZYNO) M/$ U'YAGG9J+I&;U@IHC\<6:4'EQ97+*'\O/ 6G M>IQ7:Q>5?A%NIDX6D[% M:K%:OJ+O:/#S*.H[^M_]?*3W>-!['/4>OZ#WZ\WME5B*=^+-1+ZN[[8B@5*C MTBI3BM;(-E>!;9_P)XRJ07$6C)YTAD 5QD? M7!N++,ERN8CEXMUO\=QW*EN=Q-;O_B.DARE;M[J4C&"SCSK6E+5.!07K+'-U MGU72E"0N;5TK'SO /_[^MX^KU>+3^NHR7BT__7,FSJ./P*_W4U;DZ3!#N17& M!D#-=)N3 O"%M%RKGRFK6\=3#OZJU4NH7HS6V":]?QN8IS6;-.S\O,:!&8R M,I+9&F?#87 S<1N!OS'8OK*M!D02W(39?&;-GZU)76Z(2J_KH [FF ^!$X#% ME:-@>W9R 3U]#/\5\?/9/4DGB,M;?*:,Z@VYOD 74YC12? TRDZ"H")I5[,-SG"?(#C=X/=/18&_RU M.1>>QVG*9^(&CV3,DJFD(:*I,CG7B& M/844*AG ZIYS@NX;S#N.^Y.P,9ZG<5O&U./\R3%F(80K;[7*4VE*'9M'6@Y@ MXEG8T7A\ZCLYG-FR593V&](O),QL1VQ:7%BDX0L%^K3O%-:&E+?_5[G.UK.W ME.9YK.7'X4EIB];42+./',C8;=N:&QTL8RM0F8JI\\./Q],/QQ^FB\4BHC=4 MIACRLL+0,MFH(*.W/[P_.N*#,W%!F6Q]'VB?0J1BAWUL?*>T[GE $:0ST/94 M.ZH[IRU6L 9\>\P<#[]2GD)G2H->)V>VR3W+.*G\ZWHK9]LR=1Q@!-DM_-$F13K5CN2,*3VT)10L?NQ:* M()HU)V:7^,_H0!7(C296+[-*07$\H]E_!C28DCF(8^-C(+XM.'A<^9GTE2BP MMJ:T?N"+!7S;--8],L]C:?GADW_&4A>@OMO;*$3W@8U$'XJ6">\QY-%5C-4! MRH&@QYG_AA#-Q-<19WAJF* 2*6B2[9%H5P(0'HC<2J69S:G@I: 8/^C/H"[1 M"FO?55[/_0@QID#QP/93=E0J_9'FL;/E4:!<(BY;RTN+5H$+0I3:HAT" MC+LC'C&I3[$UMI,>7XF#*I+?-K[$ Y=J8TBOM,CUAR MRC#8&4X_I>4FX>@TIZ\" M,B ]BU,L[20%[BPLI2SS[0:]$7$ %;EM-PC:!A]Z!VN@!PV,0^AX.0&9UG1C M:9@6<1# O13!1-B;]C@DR&CTQWJ@@K_X$@T6JR.G8]'RJ!=4%,2L6-/-S\QN MD4@=4N8JTRB5F *AVU9P3RR2B)4UCQ3_PEFMDBY%HZ&9>1,8N<0O<_/PJHM]D=>SOGO-T$?.7'$B/$_J%;,!LR]"\[LI&#A4K=8%RN7X;M;TB5!GM& M'U+LMY@.<70 !?=-..D??1V\"@5\<#--/CQOOQ&J-8FD!UB?1&5W& MNFI;A MODV.Q\W!0>/;C#>THM7=8N%CEF$P^-FAK\OYZ$L=)5S&WR/0?SBKTD?[\'3X MR>,\?>D_'$^_EV G*3$C,-<*B"YF']Y/A$N_0:2;8)OXW;^Q ?TB7E;X8B#' M!_">%ZG^A@T,/P2=_1=02P,$% @ #6>Q4E ;N@Z6%P &D4 !@ !X M;"]W;W)K-B>G8F-V/W0;A*L(RO/EUD) MO7\NRJ_5W)A:?5]D>?7;BWE=+]^^?EW%<[/05:]8FAR_S(IRH6M\+1]?5\O2 MZ(0G+;+7!_W^R>N%3O,7'][SL]ORP_NBJ;,T-[>EJIK%0I>K+_4CV9JZL_+VQ+?7OM5DG1A\BHMS(7)LMH(9#QS:[YPF])$\// M;O5+/CO.\J K7_^KOE0S#AK+]CPH&=<,!TRT9,Y4==ZP_OR^)9E30: MJ]$'/BK/!G%I3D*9UB5^33&O_C#]?'T]O/N;NKE4T_&GR?AR?#&/))W=Y+F\D4*W\< MWH]O)F_5_=RHN("X\LHD]*DJLC31-;[,TESG<:HS5=5X &.M*Y7F<=8D1M68 MI^.X:.AA,5/7.I_KNM:YFL8I1J:S-([4.(][D=)YHE(,>YX76;92Q7..U:OF MH4J3%+Y"79M:9UD:-XN>&F;8+GW,:;[.:^Q7FS(N%DN=KV"A&2@R%:]8ESJO M-)M_I>;ZR:@'8W)ELA261 ?HJ<_3$1UY-+T?@W&CJ1P7_FVI2\U^ Y3O.";Q M@MQB6J]@M?7D695*FI(XU\YA/H(A!>0T[(C<\<#I6L6S M8EV6*YKTI+/&$W_D1BY&D_N[P(UL,)CF>!^A2ZB22:RQI#DI9:*:)9'U\N"X'_7[?:;% MZ'@>*!U&UFG=,&^?C8(+2531E.W"*5@\M#X()_7A@B7QT<1F\6!*][0?\2(Z M$>J\0\'LEWV>\7)P=,BTF.^Q,8F3_2;IY&< F=3MWJML2X*J$G-@.P/ E,Y/X &TIRH2LIH9&5'5/C_%,XL$0=V/\J]/$B1(//>7/ M6/GE8?^8K!=F/D_A#$H2:P6ZC4"0-BQT_;+G SPM##^#3)[\T@IDU<^%YP"K MH\J+?'_[4'*^\[1,[ 3928('(%*9/C2U?LC8(;MINI43E._!$'MM% EU4+25 M>$2':37R 2ADEM;![TZ]X!OK7W2,M,$6>IX->>Z&(8ZC"- *D%%H@M 7W@S\ MO*Z:+?2*8H]%/NQNEGA4%BN=$>Z@^$OI%HD@H>ZSB2\*_(^CUD.6"KH+$57+Z#@RT"@MI5#0GV_Z&NGAL@IYS(3$F/!OVN M'A$CUS53$Y#+&YWY76:&^?AR(%SD:/M/:O7'SR-U>7=SK>Y_'ZGI\(J3%>?! M)W O'(4#L$X!.\,7(&4.-6IN,M&1"F!.I<1JDHG%E8AA#Q#>2G(';$Z9#&#G M@R"0)[8>*!MT)>519=$\SF4MA,PY"U+G_@=)'QIB)&P#5KE8 "!!J!GQ 62T MY%GE7R=1&!\@A<Z*N?E>V[2-?1YKP+>&$YVXM&[,2@ > M" 25%=5(PHP\"++7\#<#+P3ZUOK'@-ER,']1L4_^EZZ^+7-;"_.B 78QRU2I6$A&DAB"((S>6)WS@L/J,VLOO&&.-,[Y M%WSEO)AHL@X9+IOU#[_516F+/3+2@CB7^C#]K6?@DR\9Q,Z:/*EV9?J5P PJ MK_#:ZYE\*M$80B4 +2[W31\27U4V9]=/.LTX#'O#;1?M.1Q#ZS06EH'Z=3^W MEG<&3I3.UN38GC/)38]'5%.ZQ1$!:EJ @:_HMSTYR29X[-W/>PY@@(.UU!@F6FS<#DL9;WR Q78."YQ 4\*,SUU24ML'GP+&1!U MP'D.54CJ@B-<^*P)DF!AS(W(06JCT#L7^8A#'@(L*!IGZ5RT-@!>,@A#EL14908N"1FH;]*(""%8XF*&P\JP=YO M1'16#.ZL$MDJTQHSO )MT"%UZ9_3TA'* MKFVCK1RPM:\@HI$["<:)%_6>W:6QP8A(2I52C0FN#KPWV*4^FY16SLK7,#8O M119!9L77,)X@ESS\VAE:6+PUVES:TW7JWH+/UB%$!P58?->RJ+-Y3]V-OHPF MR,;N1A\>TI.Q D7W+9=#V6R-"TW*'[BN6E[[$-VRG M3&N('TY3G1?XUSO!5_3IH/_NK47B4*VJ!A3WNL0.2A=@TBVWR%<5X[_-&>J6Y.*$ NKRRA M%8BJ)'??07#/RR)@CBIB>*+NQ.M?3J;LR*A MROFLU M#S3!R3<1S2!@!]9($?!H.;WM"C_?MMACEU?*[H %;<91B0-%DB2T1 M26+'@#BWZ3@^<_5G?IQFD+O@Z*'G2>0UL M43250_HN>/FMVG4%*Y,#+PG1!K;HKE12;8]EBMFG(VOFA6,#&#PS$ M**YF='W#]FD78L6PU4Z^'"=RA1/!JF_5%4U4 ];MP<$[]5?)XVP"1](5GPVL MN*L!(76]7%:>U3N[ZL$/5G79X*^O^>T'E/W2@G8E"UUM0B&[2%Q8%(G)]J&N M;$.^BL6310WT1JN+EW#X6)0H*;D4Q%MU)+UQ-)HO+#OT+/O2;N\H8GP<%-?H M=B/]UIB P +ADVXAE/GT(SI#G>P61Z!QF,G8?Z,?X94%M <@S*^\@ MJ,ZR)Y?A0;<$* [2:NYY@"7&XB@2QJZT;RK(RVJI4"05PK:9)HA7'FZU6ZV5 MWQV;V;-:LZPZ/G=7(+&-5]WB=K5S>&0ON!E:<5M%GFQP+E+5'&!]GY!-R)ZH MO4A?ZA4)@Y^4C0GZM;69%OQUK> MM3IO3&6=;2/WND?O#A05\*"A:,6LCH0:M?RJ(Y6Q-H.V%TM59'#;N#>NJF*;?K:*B9 MY(K3#2/RMD4'(T$V)1NWU(FV.,+^K@MK&]3:I&A6D(EA,80"CD&A[6Y<@WY;21^J4ZB MP9LW?"O4_;S/_VT[^&80^;]Z]N/H[/38GC?\+&>_&@VGHVD'%2$85#9YB,4K M2>G#-=APO8L],']PT6R.&/*M0=ICRK4[*)T47(1B-W]T0%K\%YTW=)]H+S%9 M7,6V[)1A1$:5""G%BA+9O,W% 9G"@,85/-L+4^K0N[BY'JG[X7^MB=PC,Q:F M.+9:?_3[O#OW52J"9CN%-9NR1]L8\UF MWP_G?[.&P3<&6B?'^X(PWZ[DKIH"&AZPHWERUS;^5M!:JMPYKK7_$=6>/W!P M;=[I:_0]==%"F&W2V3*'I>(:R3H7W,X( [S .D9U-'[EK/!UX5;D@5?K] WW MG*BI:1<98$D)H(6/K7A)C$UN4:U4K#H&W;W>\*4??[Z=[UD0CK3U&=TI"U.U MIN*&>"XXA!U)MG5OPS9;T-36N=BXB3GVXADGTU^E?+UVHV6?$]-I0FF@/;GK M!6UY),)WL6,FX,S!_5 :A>OYS=<%)4N+XCQTNJMWV9)1VCH LC>B"$Q-52.I+W95!M@5+G[&_Z,>#8MN??J MR)AOXBF.!O>QZKC_[Z'-@CG2/^F)PX:VA8'ND:)0\WP1V&=I!?G!0".BM::/ M2%Z?,K;['JF^;TQL]9:/1;7]A;4D>J.E50[_JE4J]Q/#S?9M2#ICI?)YZ[HN M;*FXAU<*TGOAL)3X-1?JQ*PZQN-E8%M);>O'KKK\P4G?E]M'-ME1M]#8*24O MD5O"];%MP\ SFY(K:@ T-@;U"2%%%Q@Y:'KC;)A7RV9)]7#K*(]\XND MI,;PF1K)3MXPV VZ<6U&!;1)$8(V"MK'W.L*YTQH;NKN#6E -?GI ;Q M%,:8SCM,9.O/B/G:^1SX11!821(4LWM'@*7Q=87]0QCQCFN,>J:.V( M"O"E<3?<8=X=_<^YX>6Z^WRNZE9S!RU7#CGF>2 $0M-]Q[(?O#TEJ:ODM/CA MY,UI](:J;>W[,^2B/.\MM=Q.:LD,^C \)G6=4Z)//].ER%]6>5UA.)7_:HR#(SM:MS-^OD^+],@Q'$4G!R?6 MO^YF\$O5[\DI^?][WCW^ U.F]S<7_ZG.A]/11X7T\'8TF?+;E.1!7!I[%DD< ML_YH./VL)D6/?]GOPQ(IL)J\$B5A*(E(-F67T/GIU7VQQ(%.!V=[:AR^1HAP M-4'NC0A>K"!^#HET>FQV:QMCV\82:I2AMSX[KZG?W4SP^6+$%^Q$^[!Y)-C6 M=GVOGX"I'QQ&P86XNO37VN[.ZJ+;J!:,O6N;!L7]) MX7-^NNW.:WJ]4^CL].T4>4$8T'.,_0H2CX)R(RY&=^HDZYG+UI<1HP"5MT"X M;/O)NHE?MT9#Q5^A^ >$RI5.;BO7 9*WY'OXU:7^'_AK +UM?Q'A=?#W*N J M'OFOH*%3W9:".9HZTI8EL9 M9'D 21&G27(<2\95-!V'LRLS'>O:":[PRH"MI63F<89";R=1+]H?7/.B=/X@ MGHXK5N :W9?JRM N;EER+E%9KA48W$RBL][I;.#C0\!7CEM[L 9?R:W6=WZS MR"=1XA-"@9GS#(S^[O$L%NY:;S_CKIZAY\NTL.$7MDWL((T@JZW3<@>F#"17S3][V/EP !@E M+P#2'2 ->3="(5?REK9^@I)YR;+E9?Y^N; MY7QU XL5+)9GGQ:7*Y@M+M??US?SY7H<.U+QL7&V8YPUC.D+C'U8:N5*"W.5 M8_X4'U-V;8KI/L59^BKADIDN]'L=2).T]PI?ORVY'_CZ_Z7D)Q*#5F(0) 8O M2*PN;^;0AW?P+_:^2NV;]-16+,-)1%UHT=QC-#VSH#= 1F5EZU0'7(EPKF7% MU"/HK;(P3#O#WG%GF(S EHS0'K60K*#^Z%"+6;K*7!7 J5M :971BS1:B.;, M(46X \C;-Z.T=_+! K>VQAR8RH'ZWCI:>$BFI:3&HSN)PK#2+(YA*CO\2O.FLPTR8/Y4.M:# *_I-V M!0U$;R1WY(^Z)^=HE 7WCOKIH!$-,Y'<"QPJXX*S,*IHU@:)K&2JH-2=#ML# M&MZ:V ;_+>WDE%Z!8(H<9N'%7V"&\I9[*>J;RU#J2:$V'/S5:?##*))HB#&Q+5ZE6KIEJ[6G[33AK1N'O M\.:#0LH%IULO<$/0I'LRC, T0[K9.%V%P7BK'8W9L"SINX;&!]#SC=9NO_$" M[9=R^@M02P,$% @ #6>Q4G$X^E4? P +@@ !D !X;"]W;W)K&ULY5;;;ALW$/V5P<(%$D#57B0WJ2$)L!P7->#$1IRV MZ2.U.](2YF5+SEI6OKY#4MY*1>,@Z$,>\J(E.7/.S!E>1K.M=?>^121XU,KX M>=82=6=Y[NL6M?!CVZ%AR]HZ+8BG;I/[SJ%H(DBKO"J*GW(MI,D6L[AVZQ8S MVY.2!F\=^%YKX79+5'8[S\KL:>&]W+04%O+%K!,;O$/ZK;MU/,L'ED9J-%Y: M P[7\^R\/%M.@W]T^%WBUA^,(2A967L?)E?-/"M"0JBPIL @^/. %ZA4(.(T M_MIS9D/( #P&'5'[*A=IZ]SJ#!M>@5O;?;7W&OYS3PU5;Y M^ O;Y%M-,JA[3U;OP9R!EB9]Q>.^#@> U\5G -4>4,6\4Z"8Y1M!8C%S=@LN M>#-;&$2I$_WF^O+Z_@RP:O/ MP"?PUAIJ/5R:!IMC?,ZI#/E43_DLJV<)WPHWADDY@JJHRF?X)H.^2>2;?+V^ M([[IP#>-?--G^& */\(7"_W0-FBQL#-S79%3HH7X42 ME#^/X$.+<&%U)\P.\!'KGK ! 9Y'CD?&$O*9H9;7'"H1K)UPM .^L7!2%L6H M*(IQI#G"2 ]-CV#_';.JQD1"FQC#TK6 (V#5<:;$)%W,IK=]Y0NWA6FH9!-16:[;P MZ:_OX<75\N/+$=1"U7W2Q^%.BG%1GL:(D3&5H.(KHE0@/0BS_'C$E]0);1W) M3R(^#>S5X(J@D;ZVO:%8NJ"56M8..AUQ#$<<^(#6[7!"82L\G$Q3B?_G]ADN M3R,?9-,+E3;O]'O:N_+;[%V52OR.*^-9\TZL%,()E*GV<(W>G\&;/;D/)3=' MKB^FR?'E,<4(#'?4D-P 9=(R^?[7.Y0?O.$:W29V*@\1FY[S875HAN>I!_SC MGCHIR]Q(XT'AFJ'%^-5I!BYUIS0AV\6.L++$_24.6V[HZ((#V]>6I>PG(<#P M%V'Q-U!+ P04 " -9[%2AP_)8I4$ "\"P &0 'AL+W=O1]?(CT60VE6(+ MTF@CFGFQH5IK=(Y5)BDK+7&5H9V>+>8W5W?SSW!W.[]>S1=W5\OKU72D$=FL MCS*/LB?A/P"Y$!)-$0XC".WL!+ MNC 3BY?\[S!W8,<=[-C"CE^!O5[>74(*Q_"C-+X-M](B>X"Y*52FG^%C(UFU M 5U0_$E*H70D4T,R($59T7$TM&H+4=:D>H:"Y% )#4RI!E4S4:(I* ,?P++R MMG%\R)96FDHT8I460$!1K3G%8ZBQ,G6!$ETPF4--I'X>PK9@B-2WWTB""#E$ MZ3 ,0_,#51!)%8CUCB<@:G,P%> ^=8,.X>'Z 2NB@51 GZC,&!K4DF74*!V% M01BEXP#NT)D6VJUNB;)'-P=$,;YF7"A#+?:A!VQ\'<:N>Q4L,RWNJ01'GR-@[B=%_J!45;7:?:D7F$;45NM^V(O,2UQ39CT MO]&M??:!2?9P_$J*P0WA63MCDWUV>XL48XD#JG*MA3Z9=_J?;L[@T!PPZDU4)94;.S$VE4<#UM1"Z_3 ;= /[[%]02P,$% @ #6>Q4EG] <.Z P /0@ !D M !X;"]W;W)K&ULG5;;;N,V$/V5@7I!"]B6+">; M[,8VX'B][19)UDBR[?-8&EO$4J1*4G'\]QU2E]J+)"CZ8O%RYLR9&7+HZ5Z; M;[8@%<]2&.;590B7:D*U*\L]6F1,=3LXMM90CS8%3*.$V2=W&) M0D7S:5A;F_E4UTX*16L#MBY+-(=KDGH_B\91MW O=H7S"_%\6N&.'LA]K=:& M9W'/DHN2E!5:@:'M+%J,/UR?>7P _"EH;X_&X"/9:/W-3S[GLRCQ@DA2YCP# M\N>)EB2E)V(9?[><4>_2&QZ/._9/(7:.98.6EEK^)7)7S*++"'+:8BW=O=[_ M3FT\YYXOT]*&7]@WV/0B@JRV3I>M,2LHA6J^^-SFXS >S6Q^$$(-UBQ.*%^4!V=X5["=F]]\7J[N'E:P^.U^M;I=W3U. M8\>T?C/.6HKKAB)]A6("MUJYPL)*Y92?VL4=IJNTS<);]&,8#(>0)JD MXS?X)GV,D\ W^7\QGG">]9QG@?/L% =#^$\)?)OKBX);/$ (>/Q^ M *X@6.JR0G48 "E'AG(0RFE /L8[0\2WPO%!<04@**V&N-T**= QSA7"Y%"A M<0?XY>1"[8"OMF>FYTS6EN\(2)'QM2/8 M'(ZU@-Z"<%SFY6(-CK)"::EW#-$!=>2D862,*;W1^ (.A,9"K219&]:%"FJM MUHK,@,&VWKSB]@7^5HGQ5\[3YF08@PXR,HX[$:SZ6#X)DOE0;X=?F7G-3CES M-ZVC19_+/*CY U7-G0G.?262]WWN0Z8?6<.-MK"06/+G#GU700DWN-$&G38G M8=?*"1ETTW,E3 ![V7Y%HG7PA%+DD$D4I8\PH*A#5$&GA:HVMD;6QPA;9\51 M]5'E 6I1OE0H7Z3ADCM%5O!ILZ=)#*=C! L;1IU3CN.H]KTG>W(@.1=2%AQ8J%"<^G"HNL2CK\FC/=\\^R-GJI'<5'+;TDLPL/EX5,\\%JNGN_VK^-B^9)^!?>/*PL4!4E;-DU& M%^=1" VVO%S$X8%O^]D/(#WMUJ[;N(=]/\8YO\ 4$L#!!0 ( M UGL5+)KWX*#0, &L& 9 >&PO=V]R:W-H965T3C(R4^SSIC'UU%Y.%'K;2;)Y7WS<3). M3H:OLJQ\,*2+68,E;-!DO%/+D9?[R=!O_H\+>DSEVL M(52R-^8Q;.[$/!D%0J0H]P$!^7&@)2D5@)C&]R-F=\+.>>N\J8_!S*"6NG_B MCV,?+@*N1R\$9,> +/+N$T66G]'C8F9-!S9X,UI8Q%)C-).3.AS*UEM^*SG. M+Y;WZ_7=;KW:[+9PL_D,R_O-[NZ/U69YM]K.4L\9@E^:']%N>[3L!;0)K(WV ME8.5%B1^CD^9V9E>=J)WF[T*N$8[A,EX -DH&[^"-SF7.XEXD_]=[D_PTS/\ M-,)/7X#?W.]6\ '>P>^V]778OZA$Q:?N/5G(N<-2EZ1S20YV%<'2U WJ)]B3 MDG0@-XCW5 !?^KRUEK2'1VTZ1:(D0"T BR.0X[N+<3HZZ2NVM)H'9@"^0@^2 M?PZT\2<4]00-6O\$WD#(QX3(2F;&"B&8$C36Y$1AR1PDVPY2M*@XSEC>,RSG M+TO+Y7@:Q*TE9U0;*9@"NDKF%<]QJP14>&#OYR14%#S)H2C_7/,0'JPYR" 1 M#EBB0!GGN"UH"-/3(BX-V@M:D]B"/Z;.-6UB8\=:^D M49(.*!5#45\[^Z(&/D$^,)-STQVWYWLK;>@M0EXATQO^ZIJF%P)0DRVCS+EX MGK[7@K/UK*0WO8 \N_>!:GN*SX M:T V./#[PAA_VH0$Y^_+XC]02P,$% @ #6>Q4B-]*$J1 @ N 4 !D M !X;"]W;W)K&ULI511;]HP$/XKIPSMJ2,A@99U M@ 24:976%@';M$>37(C5V,YL4^B_W]F!#+2VTK27Q'>^[[OO+KD;[)1^- 6B MA;THI1D&A;75=1B:M$#!3%M5*.DF5UHP2Z;>A*;2R#(/$F481]%E*!B7P6C@ M?7,]&JBM+;G$N0:S%8+IYPF6:C<,.L'1L>";PCI'.!I4;(-+M-^JN28K;%@R M+E :KB1HS(?!N',]Z;IX'_"=X\Z0S%"RC'S[56\P ]S3!!@U816-4,DN^BFG+ MT9.SJM)JS^D'Q_(96A^3WD4413Y)J]]+G-&&EW34&9E06VD-,(V0;=$E.1'R M_ET_[EQ],F!4B421\Y0TTRZ!E )(%O.SV8J[5TU6!T\+QFGFI,OJ[+5B.OL; M1[>MRR0Y@PK?%W..)"/CFC:!JF]:/5]E^Z7O'IY,DT"]\3O#4&*JLQZLQMNL MI7$]C7_"ZYU&#=MP::#$G*!1^ZH7@*[W1&U85?G97"M+D^Z/!:U6U"Z [G.E M[-%P"9IE/?H-4$L#!!0 ( UGL5).,1369 ( $,% 9 >&PO=V]R M:W-H965T]HU]UX8&,4 MV+.;J(T/QPZV0F!__60GA'(W>KN]))*L[],/2YXUQCZX I'@N53:S:."J#J/ M8Y<56 HW-!5J/MD96PIBU>YC5UD4>0"5*DZ3Y%-<"JFCQ2S8KNUB9FI24N.U M!5>7I; O2U2FF4>CZ-5P(_<%>4.\F%5BCQNDN^K:LA;W++DL43MI-%C=J!7=F.8;=O5,/5]FE M?:%K?]#2" MK'9DR@[,&912MW_QW/7A '"6? !(.T :\FX#A2R_"!*+F34-6._-;%X(I08T M)R>UOY0-63Z5C*/%YFZY6?^\6W^_A?4]?S>SF)C6'\991[%L*=(/*,9P9305 M#M8ZQ_P]/N9T^IS2UYR6Z5'"*V&',!X-($W2T1&^<5_C./"-_Z_&=YR3GG,2 M.";1T^UJ@)R W,2OZ+GJ+Y\D%H1<% D=LY45CN@8M@G2NQGS @7+ORY9@U@:,5WG\"&T OD7$IX#G,+ETF3(< M0.HCD0: SQE6!%R0-H3Y\&^7$A\,=HEV'];7069J3>V,]];^A;AH%^/-O7U> MN!][R5U2N&-H,CR=1F#;E6T5,E58DZTA7KH@%OS*H?4.?+XSG&:G^ #]N[GX M U!+ P04 " -9[%2[6Y[B7$8 #L2@ &0 'AL+W=OUV+]\NI4X/?OM( MGSWDOWW,JC+1J7K(15$MES+??%9)MOYTT#NP'SSJ^:+$#][^]G$EYVJBRN?5 M0P[OWCHHL5ZJM-!9*G(U^W30[[W_W+O&#;3BFU;K(G@M\"K3+/N.;T;QIX,N M8J02%94(0L)_+VJ@D@0A 1X_#- #=R9N#%];Z#=T>;C,5!9JD"5_Z+A_*7.@"X4594M!?L>:U5^<'(JJ*,EN:S8#!4J?\O_QI"!%L MN.[NV7!J-IP2WGP08?E%EO*WCWFV%CFN!FCX@JY*NP$YG2)7)F4.WVK85_XV M>;Z[ZS_^7=S?B,GHZWAT,QKTQT^B/QCB/_XB'H>W M_:?A%W'7?WH:/D[$X4.6Z$BKXNCCVQ+00:!O(W/T9S[Z=,_19^(N2\M%(89I MK.+Z_K=P#7>74WN7SZ>M .]D?B+.>AUQVCWMM< [<[0Y(WAG_RNT:4'@W"%P M3@B<[T'@Z7 M:0GGE2J/LN5*IAO0L00P4@5!+'.9%I(4N! +^:+$5*E4J$2#+N %3EK(?.'( M?-%*GN?)$(D\G#R-@'?#21.!VR$@@<$HKF0NR=8 K?80%JF/ME27&]#T\F")28TE^J',@()O)'I7/X M;"E3L*=XH"@S>/=="564>DD;D*BR !N\8IJ6P% A9S,PDLSN)6*#<&&5*GE# MHN54)[K4!D"LBRC)BBIG#.!*B#\>N&\3 T>1PPWXNI$^Q'+X$DB9Y7A-1H=. MR=6+2BM%:]3/%(J1\KY/41'($@6@YC5A,S2P$IW0;LBF><;W/0BD\HA M-V!9_(]_NS[M77THQ KV 1H=,9,Z;U\*8KP$"0##'7WOU$A=%Z^4B $7_),^:)/[2R?WEZU2.^A/?B?+12^&?WL> M?>O?#L=/C0K0#NK)4X+LBXY5#NP$/5^ 6P0Q3C1()U[_!?C S%Y5>;202!16 M!%";7,]!+!(0VA(8"RI"1,Z5$DMV%5DN0#V<0 %'B7(6% K\%)E:+ 2J Y"6 MC@*-H_6P;I45++7XWHD>B3'NFD&84K01]\H1]^IUXH+='@!!'_?:[7883TWR MA5@ZHRQST"05&UNA4]3)6%0K),2;TXMNI]OMTNV5C!:!SL'*4I<5B=9:";#9 MLB/,?I 6^=621"_J$@MIRJWGW8[!$3&C)VSX+#[39=VO.F=GQ$N MZF>D5&Q%?Q=U-.QE*P.N'0.N6XGW\'C_,'Q\^CM). KWPQVPHHD)K\#)(03. M01;)\(!0K4A@D/*@GED>HYDJ0>J+\D0,T3#%0%DTC4CWI?P'_)4Q?$9&@-SD M4?^I8G:DX-Q@%UBT1$:\KB,PQ 8KA)3E1>AO=&X@+&0^ M!T2 [<8V@NE!2U?E0-43\<<"O.:J[2:E1O+#J1DP)E]K@ !F'K4%/IUUV%C" M'=D21>#'T8;!EW4S1;"6<#L(+?)L60\A:"M8"" .!,TH!'.X%"EU!DJM7>3A MO!VO)$E"W"43T:HS?+M2%-8[F_\EQ 8 (J4U @24>)/U S$:Y%F5@,B]>(N0 M*[X5.S*^=FT=!"1SC$+*-08B9\>]KM@HF;?.9E_URJKH_%3?_QU]/EV*/J3R;#9DK>#N-41B4]_#F:71724 M@I)WKSNAOQ/9M 3>D<9&[(M!]HB">'.."T#8D+_&>P)MYS(GW0_0 ?P7&+<$ MI.#%@1: 5KG.' 5( 42:IFPU\$L<'$'?G>EJ5L'T@@OXW5@"H'F3)?!]U:@P?Z7OVC\\8 &?-8*O5-%4:S% MZ 0"V-C@!$Q?.L5S^^IBMI0;].@FN"4#MX*/\FPC$PPM,<3"+!Q9T+$BR+AD M> >6W7=UH,C5G(P,;)"&V+LWX+CD-BL@88$+%&),9@6T=Z(BCD]N;P?.&GF6 M5H4*Y;]4T2+-DFR^8?-"9H(QA5B]FDE2 Q:.U0K0<$E$J">X:XGR;<0H2;)- M\9J8@T@T7(O$G?WQE (P(WLDXTN9?U>ECTI/22MP;0%.QD;\/L@%L2LJ9.S_ M0UG]K" >31%-C7+4Z];E" FY+9D28_6TDHD[9::(CF]Z3$7R[_^:5+=XBE[7 M%WZZK8;^R_-0W#S>WXFGWX=B H$_YL#[O<8KT,9@TRC8")) C$L2> ,9&'E4 ML5 )"V8!<;G0R%\4!),B@*N>@L1L.">%&V.&#!G$E .M%U)9D' 04$VK\JR: M+Q@61 8+DAZ9NB\X+:V0>Z"08 J62X@\09(2)#Z@X=$S&K>-(G,[N Z$-DIR MH&HR$$@7X%RV8: \+ITT>30R.\@9*7?!*(J\9:&2!"07! DB0EA$RDF1$,8N MD.=CH/ *BG0"EEE E' [!E0F_P9 BD#EZMB@78M<(37^DR,MH#SJE8G#3L17 M!@+KP -OK<4 OB C0+D>AX%H]+;N *&8S\U12<'J8ARVI9*]+=-<8"824+U^ M69(,4E7OG(WM,DF'X%JV) RWS[K^5:2V8AT7YP=W)!L<_Z,J$ >',/&9.849 M6._D%&)YB$@@8:]%#=O7Q!M*V +FG6V%WXCO.22!$(5-"-N=2&D,L^-?(S.? M#R( O,7U;]Y98$;'HBS!4GD=8JI^EB8#)T-+$O"CH@PRRHWM-!P LP<(Y056 M^\)*3^#9[\#(]1P3\)TWR@&Q^6+NNISLQ%5D*!V#)KGD@N3"E:L<[#X8BH0< MP?\H]*:4>"NV8 DPP Q1N1+&B5>L,.ZAD)'$.L$:II ?6_L";ZG$ M@3@9+P!^@N0/OBNSW!01>:6)'&V&1_A[RT W7U'D/*O2N-V+!.V#7JO=O^L_ M_G7XU,>,8S(OG1DD*Q84*:DT!U9" M5TM;-L!" W^!163RD52DYGK?B;A!$+L7;T #6!U0GMPFY-'!%08N;01.$#,6 MBOG '0?0 >N%D4(N'%EB9)#H[XI#D92^]G[T2A/'(Z]P@VBM,6,9P [>#!O9?7<:DQ9=^QG48*F')CX%W1G 3K MV(HZRV[S^&!%A^O17(X*VF/.&NP3GUU,"ZOE6_$^@4*-0+6BYJ9#R"8ROW8' M'Z(W>IL;<[M:.X5CQ>UPIA:1F%C3DZAV>&L0<>J#B--6Y_\X_#8<0SKZ.!S< M?QV/]C5+7H$2AA".((7K&Z++B/ >?"T,)QJZK,WM6$PG>*+%5:9O7"FW[[=, M2I YL-3B4]Q%>GW0\W_MG[<-2TK0#\8Q]WV&W]R<#MNNQ>=L2C MN=(-*NH 6)F#B3,ATH!F1L@(LH4CJUAP17:&B1JXZA49,6.S$8.H#B2R0(CC MEH*&J(C;>W&HCP086QP"V)B(@4'8B%0Y*!]@L5M=;FR-AT:*D!?9--%S4]HW MU+7 :"OL=:$.R["?"N 0!Y>]')'4HEGI%PK VVS%Q:R!'MP4Y%SW,Z<:?4%()^(/K%TG-DNN MDW0K_^&&#%9Y5*OE\!,ZO;-6G;_ICQ[%M_[M,U6O;D;C_G@PZM^*T7CR]/A\ MMZ^9W0X5)^'>%RL9J4\'Y+CR%W70;%[B;2]0F_P(0NPF\X/F0(!RBVO,@6\0 MR#<"K->S%OOB!BXZPQJ1YO;$45ON-<&#G9);+I<(9.6Y,TAX4BP![SH&^ M]OL/)XR/;B<*J#_RC&@ M#ZR";>+99 DR9XU'!36-L&Z&-0W.V@IKYF524,-58BX13L7(*?B+&O_#PN%6 M @E)(&B$+A;,IB!0UN">P#=O?%/*S/@@K8PQ157_"5'*G\HV*ZE;.D6QI21* MIZO*R!%8T)V55;J[EG2W24*V[@^"!:G!E.)0#"L2;-^1I3" 2#!,M9OF7Q!= MID0 ];VXQ8VB1[+=._T@_L9IK,E?D;OL/2!4WC=CI.V(I^%G\<% /6V!:I/A M7X?YHP6S7P)H()G(W>13? I[J&46J^08Q)5TR!44:3.+@=R9GW,<#C]F(8IS MJLK1435.[UP-]S/)SAS)OOGC+4:4'@1U3NQNZ1^5"A#,P%&3NL*9#8@2G=KP M#&6R7C@%B8.=E/KL3/D 1DH9(R[6^GFYP'.ZP,\?M=4)L60FRVK4LJC9W'V.Y#T=OM5G M*/8N[YB1"@KR:'0HC7_=PM;,E?'B@">Q%)8Z#<6 8%KX@H=8Y%*JEMRBL*52]H_5J=_VJK MB&$3X( --(W'>E[6& JB,UK*.7[[66?%!L+J9<'3L&#%QQ!$,\9/7'O3266K93A/FQ<+O;*N(%'2I>*Q\C.]9KTY"$LG-6FW M**.6[7-)P*45#_Y@D@!B F[&#+$X?#ELN3CN=5D;YI7FR(8RQX*]D^9B"9$U MM/RV,>XE-C"7_L/0-3W=Y$D8 M9FZ3RHQT-4,"J^)$F4,P?^<.>P_?%[!5K7J-CM&480QCZN!F,A<;03+'O )P MN:_R9F:&+$2;I7>DS0DA4@!O7.6D!5Q/:K 8W7V=?6/]?1XSRU 6 1C83#+6 MH9#OS O4@X,=]]@\=B4G >:Z_[$95AR8>J:]NBK_,RK.C0"!-ZXWR M4N^RWHC+3N_=.^IDU5\?T[^FB^]:V_^K=[_H7%]=F/N&K_GN;1FF?P2CU_[L MQ.VP/]G3T7K]H0OK6,!8%R:XC]AJ<)'$#D!1.8XL)+VPWF8!-OY'!6F)RHMZ M&"3CC,I59(;/3U%Y_B+3"ENOIM]+6H*V*FQ(NE(C52#!*-O!G\9A?-\3PS0, M10*YCXX_UERZ5/9F1O=(\^A2OA2*L2"ZX(YM2N;<$]&%F2[P_1,_!^MA.U?^ MEPH [0X,U&>Y*-D$ ?,M>C> C[@11%^@2F!%@C4+KA2S[)J\RMIIWD(!AZW' M^MYR:Q'#/W[2:W]Z9#0>W-\-Q5/_/_<(VNL/GSBYL/$:B1!7@$OYT[4W738> M&N<-!VPR6J"0<8V&ACS YV7)"YGN^B,+("+@!E#:$,Y*85&)4F0]@[1>T?"W MS:[+/>%J.%JSY2GJH[+!@QUV?-^VMRTX2BWK5_9SM1RM.XQ#',TP*5B76,&' M)(:PM1DM&WF%=0XNBQLMVGT4)'C0JC:?TE@.0EV^.G<#J+XJ4//^OFIL9L - M;0I70W;SB/Q4#R7C7A#J=F19%:5I++&T8]M3+[+,6 NT0DVDV1W,HJQP5E%( M#@N-1:=S 3$WQ&;[;P$.4SA1O=A>EFN5&OO C=BMH5#$VM$'S*K/1EWCXD0, M?Q)V&/<05.UY8Z_I;U4= H8QA=8T>4,UL,+HT51M9*UMC#:>@1T&H#!&. MC)F!SAW=]&/LOOI%RHW$,=UXN)G\SN7UK3:?^1R)CAMR!=*3V@EA3R-FOO58 M,^[\VR0@Y$9F)\'3;48Q:!:<:6W\S<[QX?,3J M!@\_, ARS"!ZC-SNF60!" MO@!8//E=K? *%7;%3)L0TE6%14H\FU2U@NR)&Z+]UY GU>)F8(W'-)Z WCMH M4HN+[K^'.@O$X:E:AQP<:.8ZL,_5"27/E89=[I:A'0PDHK,U"=/A)S65>0ID MI5(WKNKEEJZ%O8>ET21\E,T+AWNJ4W/_I+\[U ^<3DBH7#:[+0L-=?BPY<$# M*39P9+MF71VK54UY' _,@'%[5],_7==K?R8.G]X=T--'7T:WS_AD\+#_.!Z- MOTX@QKV?3([$P_!13'[O/PX;O7X[]%%+/^'TLNO:!$.3I(D'T*D)3G!W3/6! M"(-I5F2F9V !C7BCX&/AHC*-[UB#G%C73TNW![S#>7 T(%C',ZJPIN?B4=' MJLNY$FE%N4F,[P)KF[^USG5P[>0F] M8.WQ2K1&:XA*I+6*8+D!P9)R="YG?4$0*%EPIDUUPU-#]+?&L?RC0/;ZQ__2 M]3OU&:L]%ZQ-Y=?*>_7"J#F1:_.('IH:GN)G6^;J&=M +?&08)9Z-)UC-!T; M![FR@PEAO:#SWZ>&X^O^^]EJ84E#V%3Q)*_L0C5 5!];DK4\V7 M[ZXZ[[!*Z)\T0R/J:&^PI8ED@V8P/N.B9COPQO+TFBQU7)/-<98+G)8VOO(2 M2#]?U3\B7[OQ!['(UA!CY7MP=X_=O8:[T;TZLZQ(OCI:PK&G*\L(MA\0UX8]0!&O]JW&UQ,@MR]^+\8[Y>2-Z M9^>FZG!X=48/RX@C\46E&?U" >[Z8UOJ^6(-HGYQ\:YS>MWK="_/X?55Y\J\ M'CI)\.SS=9!>KW-^<8F"*HYW#[.T,\==7'4[5V<@UM<]<7'^KG-V>=ZY/+TT M]G4_@=^([@G?DOX_T>57_6'6O_9GHR=/]X*_'X%O!GT+:_# <3_8^ M7=T.JKG-#\;,5AJN.^Q2C6GL3Y[%.#NA;XZ[8!0P"E%IP?)*<32=D1%PV(,9\_930B>M]2S_5'2O M_7'FQR$^D5[[$9/'^S&\'@SWCTNT@P22]:LYAM;^T8EMPA'1>F>=8)1!W+B! M!-MM'-0G+(.UCW[:E0U.\_A#O5>8*W@!"O.7#4(YQ32$A\^9SQKLU]9 MFF&<[AA%EA62PPSS5VHCU"IHV]EEXX/+G2!S\LE*[@X'KG[[)U!+ P04 " -9[%2&/6N9I0# )"0 &0 'AL M+W=O-OE7X@^-1G#.#63QT? ,(4XRT\<#H M<\ )IJEQ1#"^53Z=.J0Q/)=/WA\M=^*R80HG(OW*8YT,G9X#,6Y9D>JE./Z& M%1\+,!*ILO]P+'6[H0-1H;3(*F-"D/&\_++O51[.#'K^!8.P,@@M[C*01?G M-!L-I#B"--KDS0B6JK4F<#PWF[+2DE8YV>G1ZG4^'R__A.='6,V^+&:/L\EX ML8;Q9/+\NEC/%E_@Y?EI-IE-5S!>/,!R^C1>3Q]@/EZOI\L5W*S9)D75&'B: MP!B77E0%OB\#AQ<"-V$N#C"X.X#&AY1&YJN#>/.$!TZ !*[[+^9:6 M#!N=H 2Q,<%-69&S?5$K0_A>N\@O:C8;,,L/J+1-$D'";P77/T!A5$B;'_@$ M'3?H]UW?]W^2/]O?1\0?,,)L0Q K[O[_EGO;[77;%=]SN>1^I7;;=>VV_W7M MTJ7)(UN@,4\+DR]D,N?YCC"G0JD&[(FZ2IC$C\KV:J!+99M(Q'<7S,]5^V[H MPZ+(4#(MY!TLT*0M$AF>X'V"H-FJ,G33;896;% YY()NY-+JJ[W^,?[,#N1H MAQ5KRTH!=4.E*0-$&MKMOAOV M?OM$CNNMU*GFZWU*E,PFR:3!F=[5D0N*UV MQ^T'7=J@7X*=$EN%:W=]M]OLNOU> .U6WVUV6FXG[,"]Q70Q^T3/ORU9VB]1 M_*<-^\7DH]KQSMH3I7EGF[""2!2Y+CM5/5OW^7'9WOY6+Q\)M&T[GBM(<4NF M_FV7JD.6C;<<:+&WS6XC-+5.*R;T5D%I%&A]*^C$5@,3H'[]C/X"4$L#!!0 M ( UGL5(I&4_M9@( !\% 9 >&PO=V]R:W-H965TJLTQZ)?;91,7B DW9_ M_0 G7BJU>=B+S<']/@XXICNIGG6%:."EYD+/2&5,-K3$%,V/YD'9*.A9CYV^3[AB>%.'XW! M5;*1\MD%23XCH3.$'#/C&*C];?$6.7=$UL;O/2?I)1WP>'Q@_^IKM[5LJ,9; MR7^RW%0ST#D?7="WN4=-32>*KD#Y;(MFQOX4CW:FF/"'4IJE%UE%F?B M9/6T2-?+Q6H-R0J2Y:W3P.H].$BZI.H/1< !1& U/\(WZVD>>;_2? MM9^0&/<28R\Q_D BM4V4MQQ!%I!55)2HP4@P%0(36]3&WF]CAY#4M+2W]+U= M/JG@FO9:-S3#&;%=J5%MD<0PIYR*#(%JIWR'&=8;5(?-"^$33 :7%Y-!&(9P MZWTY$\Y6*VQO<_8'43W]O)X.C2UJA*WYH:,MD*T]W??K;O_IONTO]+[YX.JUPRH8%C8:'AV<6$ M@.K:L0N,;'P+;*2Q#>6'E7W!4+D$NUY(:0Z!$^C?Q/@O4$L#!!0 ( UG ML5)I)LYA*@( ,D$ 9 >&PO=V]R:W-H965TYYQ,&Z5?3(%HX:T2TB2LL+:>!(')"JRX&:H:)>ULE*ZXI:G> M!J;6R',OJD00A^%U4/%2LG3JUY8ZG:J=%:7$I0:SJRJNW^*O$KS*W M1<)N&.2XX3MAGU3S%;M\KAPO4\+X)S1M;'S-(-L9JZI.3 ZJ4K9O_M;=PX'@ M)CPAB#M!['VW!WF7=]SR=*I5 ]I%$\T-?*I>3>9*Z3[*RFK:+4EGT\?OSXL5 M+&>_9_/[!5P\\[5 E44#-7]WEN$31%?A( Q#N$=C M)G#7G6: :EP>A5Z,V\#+8\0 )#6[<]M+"1JUL1]=2'!07A7JK6\B U[;5EJ_ MVO?IK"W/?^%MD]-7W9;2@, -2&PO M=V]R:W-H965TYP5IPU/=T+^:!VB!J> MRJ)2,V^G=7WA^RK=8]DC3S>Y:, MEU@I+BJ0N)UYB_#B,C'Q-N 'Q[T:C,%4LA'BP4RNLYD7&$%88*H- Z/'(RZQ M* P1R?C'<7K]EB9Q..[8_[2U4RT;IG IBI\\T[N9=^Y!AEO6%/I.[+^BJ\<* M3$6A[#?L76S@0=HH+4J73 I*7K5/]N3>PW])B%Q"9'6W&UF57YAF\ZD4>Y F MFMC,P)9JLTDKYHM\GZ3U^J).WV5TE/ [DV.(PQ%$ M010>X8O[>F/+%_^/>H_03GK:B:6=O$.[;CT-8@M+4=:L>OY# 1U>^@"B?K$? MU\^'WNE1;M.6%ZIF*0V'H^AS8L=_2589 MH:&=6HAR(O@\CH,A&+MG5V@&G]SGZJGFDN8?PC[XH^$XM:MO%9/-TEWO,XBC M7^4FX_.SUW X2IS<(_Y)>O\D1_W3'U5MCDH!B8.].Z]/S)U72JTER4<-*Z"@ MWS*K?&@R EXJ.V2THR+>,5IGAN%+.V207]SFW#3,.F+ Y: T:\;?F=G1#P7\ M+L6>9 )Q[XC).$K>H@XX:>V2#*+C Z@#G$M.!W[MHH>H \PCG SVC#LEKU ' MG+3F)]]WYK-]\!9VR"$[^H,;HD29VWM0D:.:2K>718_V5^VBO6%>PMM[FEHE MI_:' K>4&HS/R%2RO?O:B1:UO6\V0M/M98<[^KN T@30^E8(W4W,!OT?D/F_ M4$L#!!0 ( UGL5) @@&[& ( /@$ 9 >&PO=V]R:W-H965T!2R2E)2P(8C4>4YYG_G M0%D]M5SKM+$EATSJ#3L*2WR &.1KN>$JLCN6E.10",(*Q&$_M6;NPR+0^2;A M-X%:]-9(.]DQ]JZ#53JU'"T(*"12,V#U.<("*-5$2L:?EM/J2FI@?WUB?S+> ME9<=%K!@](VD,IM:$PNEL,<5E5M6_X36SU#S)8P*\XOJ)G?H62BIA&1Y"U8* M/\+\%N ;XPVRHRM)98X"CFK$=?9BDTO3&\,6KDA MA?X78\G5*5$X&O M\1+=_+@-;:D*:[B=M$7F31'O0I%?F ^0[]XAS_'<,_#%=?@2D@[N?(;;RF[G MV>L\>X;/_Z[G*[7\KI9O:@47:LV2I,HKBB6D>KI(0N2Y_C4D(T.B+]XQNA\% MXV#L.,KPL=^JLYF3B=O/_*0TZ)0&5Y6^J>M&B@-*<$DDIM?4!E\U#'W_JP*[ M-Y?Z35!S<""%0!3V"ND,QD,+\>:>-8%DI1G5'9-J\,TR4T\3<)V@SO>,R5.@ MI[][[*)_4$L#!!0 ( UGL5)5XXIWW0( -L( 9 >&PO=V]R:W-H M965T_+>QZ(G>Z>\4>Q193P%(6QZ!E; M*9-KTQ3!%B,BKEB"L;JS9CPB4DWYQA0)1[+*1%%H.I;5-"-"8Z/?S=:FO-]E MJ0QIC%,.(HTBPI]O,&3[GF$;+PLSNME*O6#VNPG9H(]RD4RYFIFERXI&& O* M8N"X[AD#^]JU+2W(*KY2W(N#,>A6EHP]ZHFWZAF63H0A!E);$'79H8MAJ)U4 MCE^%J5%^IQ8>CE_<;[/F53-+(M!EX3>ZDMN>T39@A6N2AG+&]I^Q:*BA_0(6 MBNP3]D6M94"0"LFB0JP21#3.K^2I '$@L.OO")Q"X)PJJ!6"6M9HGBQK:T@D MZ7+@%W[N;>+>>.YC, M8>"Z#XO)W)O6P(V&*\&.,T1+YSPH:]=*[?FX: MN6'COS2.ZRII-,K$CQ4H.' M.'HA P V @ !D !X;"]W;W)K&ULE9;;;N(P M$(9?Q8KVHI6VS9$$*D#BU"Y2H170K?;230:PFMBL;4KW[==VTI1#R&YO('9F M_GS_Q/:DO6/\5:P!)'K/4BHZUEK*S8UMBW@-&1;7; -4W5DRGF&IAGQEBPT' MG)BD++4]QPGM#!-J==MF[I%WVVPK4T+AD2.QS3+,__0A9;N.Y5H?$S.R6DL] M87?;&[R".!G=B[1MK*"V.O M>C!..I:CB2"%6&H)K/[>8 !IJI44Q^]"U"J?J1/WKS_4;XUY9>8%"QBP])DD M%&(O M0>E4)WA%@G><$)Q)\(L$WQC-R8RM(9:XV^9LA[B.5FKZPM3&9"LWA.K7.)=< MW24J3W;G3Y-);_8+/=RB^?AN.KX=#WK3!>H-!@]/T\5X>H<>'^['@_%HCGK3 M(9J-[GN+T1!->HO%:#9'%T.0F*0"N9?H"CW-A^CBVV7;EHI,Z]MQ0='/*;PS M%#Z:,"K7 HUH LEAOJT,W-6)!*188L>"TW7"X*@859%1=!AYP!^5_%$M M_VBY5*<68DN4D'2KSRTD(-YR(@F(*N;HA,1U@T;8PJV.9IV2(G\J-6TSVBK8@,6GX8A%Y83=TJJ5NUU'VS'@!SJA:!*+8% MV@#/L:NH6RH0ZCE6F= M L5L2V5^KI:S97ONF:9T--_7;=OTGD^9O.>K4W-%J$ I+)6D&PO=V]R:W-H965T8W=$!R&F!WN24#W M=PVS<1Q8^INM4 /-X6"'-V1%Q,MNP>1=,[?B^2&)N$\C8&1]U[#-VP=D*4 R MXP^?[/G)-:A07BG]KFZFWEW#4(Q(0%RA3&#Y\T8<$@3*DN3Q(S/:R'TJX.GU MT?HD"5X&\XHY<6CPS??$]J[1:X!'UC@.Q)+N?R=90&UESZ4!3_[#/IMK-,"- MN:!A!I8,0C]*?_%[MA G &FG&H R *H+L#* =0YH70"T,D#K'-"Y &AG@'9= M#YT,T*D+Z&: ;I*L='63U(RPP,,!HWM@:K:TIBZ2_"9HF1$_4EMQ)9A\ZDN< M&*Y>9C-[^2<\36 U?9A/)U/'GC^#[3A/+_/GZ?P!%D^/4V.L:?GS%/](8:,JES=<7'=?W'FDMSO !+/-70 8R MJN*YAF8W1[A9 1_5AU=Y'^OA(^)JX9/:<+-? 7^H#^]I,F'E.]U*[+4NV+,C MX7M^$*M-"IRX,?.%3SB0=S>(9;)AS6@(+@UWL<")3-(U$,PB/]IPV!&IWUO, M"."0QI&HRF7JOYWX5R7@;=A&;;/3-B3]MPKFK9QY2\M\P:A+B,=3AAP'1%'# MG!/!84L"29VR9+SJC4MM=TY868;ZRSFEY.M-FUR=]B'"=AYANUZ$.WS KS*^ MST3JM$OKK^/6R;EUM-P,[E1+N^ 3HD!:I<7<=PI+>+9M ]$ MNSG1[G6B2@];2A+HKHH%47* MOM@%53+4*[GO:_+>SSGT]7KA_2/+KUI Y1C>'J M_9#6K8HIEMGI=_MF]P)O5/!&6MXSN7'".(2_9D3Q_5M3.LRB=ICZXB$%2E8 M<0 <>4!^Q/Y.MN,"8D[6<0"!+"G5*Z&W:L%!%ABN8UC4"%-?)&;XO7;8A2R; M5W7Y4V'KK9K&];@+=3;U\KS 0E$*?%=^'\GJO&&$)"2/"P'_PB/E8 =22E2? MJMYA', J[0 .\/CHG,Z=1K+A,'JUUK%09E,OS1/LLT1!DI=9]ABA;"]D;^]^ M!Y_S^$*K6U9?RVA??K,+<37UZFJ'E G_9]KDR/SZM-J_WDJ=+!9::^K%]O_) M8K].%E$AQD@OQI_*(BH+M&5=3"(JY!GIY;EF$J]8J9%$5"@OTBNO'44Q#O(D MKDEEEY89^5"Q+M*,&PO=V]R:W-H965T]Y[KFS[GH[(5]5@:CAK61<];U"Z\V#[ZNTP)*H&[%!;FYR(4NBC2G7 MOMI())D#E
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end XML 44 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 72 248 1 false 33 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://mhtx.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://mhtx.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://mhtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://mhtx.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Sheet http://mhtx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Statements 5 false false R6.htm 000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://mhtx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 000007 - Disclosure - BASIS OF PRESENTATION Sheet http://mhtx.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 7 false false R8.htm 000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMatters SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS Notes 8 false false R9.htm 000009 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS Sheet http://mhtx.com/role/InvestmentInImagionBiosystems INVESTMENT IN IMAGION BIOSYSTEMS Notes 9 false false R10.htm 000010 - Disclosure - NOTES PAYABLE Notes http://mhtx.com/role/NotesPayable NOTES PAYABLE Notes 10 false false R11.htm 000011 - Disclosure - CAPITAL TRANSACTIONS Sheet http://mhtx.com/role/CapitalTransactions CAPITAL TRANSACTIONS Notes 11 false false R12.htm 000012 - Disclosure - LICENSE AGREEMENT Sheet http://mhtx.com/role/LicenseAgreement LICENSE AGREEMENT Notes 12 false false R13.htm 000013 - Disclosure - COMMITMENTS AND CONTIGENCIES Sheet http://mhtx.com/role/CommitmentsAndContigencies COMMITMENTS AND CONTIGENCIES Notes 13 false false R14.htm 000014 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://mhtx.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 14 false false R15.htm 000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://mhtx.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) Policies 16 false false R17.htm 000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables) Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables) Tables http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMatters 17 false false R18.htm 000018 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Tables) Sheet http://mhtx.com/role/InvestmentInImagionBiosystemsTables INVESTMENT IN IMAGION BIOSYSTEMS (Tables) Tables http://mhtx.com/role/InvestmentInImagionBiosystems 18 false false R19.htm 000019 - Disclosure - NOTES PAYABLE (Tables) Notes http://mhtx.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://mhtx.com/role/NotesPayable 19 false false R20.htm 000020 - Disclosure - CAPITAL TRANSACTIONS (Tables) Sheet http://mhtx.com/role/CapitalTransactionsTables CAPITAL TRANSACTIONS (Tables) Tables http://mhtx.com/role/CapitalTransactions 20 false false R21.htm 000021 - Disclosure - BASIS OF PRESENTATION (Details Narrative) Sheet http://mhtx.com/role/BasisOfPresentationDetailsNarrative BASIS OF PRESENTATION (Details Narrative) Details http://mhtx.com/role/BasisOfPresentation 21 false false R22.htm 000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) Details http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables 22 false false R23.htm 000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1) Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1) Details http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables 23 false false R24.htm 000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) Details http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables 24 false false R25.htm 000025 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details) Sheet http://mhtx.com/role/InvestmentInImagionBiosystemsDetails INVESTMENT IN IMAGION BIOSYSTEMS (Details) Details http://mhtx.com/role/InvestmentInImagionBiosystemsTables 25 false false R26.htm 000026 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) Sheet http://mhtx.com/role/InvestmentInImagionBiosystemsDetailsNarrative INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) Details http://mhtx.com/role/InvestmentInImagionBiosystemsTables 26 false false R27.htm 000027 - Disclosure - NOTES PAYABLE (Details) Notes http://mhtx.com/role/NotesPayableDetails NOTES PAYABLE (Details) Details http://mhtx.com/role/NotesPayableTables 27 false false R28.htm 000028 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://mhtx.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://mhtx.com/role/NotesPayableTables 28 false false R29.htm 000029 - Disclosure - CAPITAL TRANSACTIONS (Details) Sheet http://mhtx.com/role/CapitalTransactionsDetails CAPITAL TRANSACTIONS (Details) Details http://mhtx.com/role/CapitalTransactionsTables 29 false false R30.htm 000030 - Disclosure - CAPITAL TRANSACTIONS (Details 1) Sheet http://mhtx.com/role/CapitalTransactionsDetails1 CAPITAL TRANSACTIONS (Details 1) Details http://mhtx.com/role/CapitalTransactionsTables 30 false false R31.htm 000031 - Disclosure - CAPITAL TRANSACTIONS (Details Narrative) Sheet http://mhtx.com/role/CapitalTransactionsDetailsNarrative CAPITAL TRANSACTIONS (Details Narrative) Details http://mhtx.com/role/CapitalTransactionsTables 31 false false R32.htm 000032 - Disclosure - LICENSE AGREEMENT (Details Narrative) Sheet http://mhtx.com/role/LicenseAgreementDetailsNarrative LICENSE AGREEMENT (Details Narrative) Details http://mhtx.com/role/LicenseAgreement 32 false false R33.htm 000033 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://mhtx.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://mhtx.com/role/RelatedPartyTransactions 33 false false All Reports Book All Reports mhtx-20210331.xml mhtx-20210331.xsd mhtx-20210331_cal.xml mhtx-20210331_def.xml mhtx-20210331_lab.xml mhtx-20210331_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true ZIP 48 0001477932-21-003259-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-21-003259-xbrl.zip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end